Seelos Therapeutics (SEELQ) 10-K 16 Mar 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Mar. 11, 2015	Jun. 30, 2014
Document Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	APRI
Entity Registrant Name	APRICUS BIOSCIENCES, INC.
Entity Central Index Key	1017491
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		50,414,481
Entity Public Float			$85.40

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets
Cash and cash equivalents	$11,400	$21,405
Accounts receivable	678	59
Restricted cash	290	332
Inventories	275	336
Prepaid expenses and other current assets	646	132
Total current assets	13,289	22,264
Property and equipment, net	1,358	955
Other long term assets	162	91
Total assets	14,809	23,310
Current liabilities
Notes payable	153	0
Convertible notes payable, net	0	2,600
Accounts payable	860	926
Accrued expenses	4,555	2,119
Accrued compensation	1,112	952
Deferred revenue	226	1,800
Derivative liability	0	517
Deconsolidation of former French Subsidiaries	0	2,846
Total current liabilities	6,906	11,760
Long term liabilities
Notes payable, net	4,626	0
Deferred revenue	1,000	0
Other long term liabilities	358	578
Total liabilities	12,890	12,338
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of December 31, 2014 and 2013	0	0
Common stock, $.001 par value, 75,000,000 shares authorized, 44,330,006 and 37,541,404 issued and outstanding as of December 31, 2014 and 2013, respectively	44	38
Additional paid-in-capital	291,727	279,000
Accumulated deficit	-289,852	-268,066
Total stockholders’ equity	1,919	10,972
Total liabilities and stockholders’ equity	$14,809	$23,310

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value (USD per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock issued	0	0
Preferred stock shares outstanding	0	0
Common stock, par value (USD per share)	$0.00	$0.00
Common stock shares authorized	75,000,000	75,000,000
Common stock, issued	44,330,006	37,541,404
Common stock, outstanding	44,330,006	37,541,404

Consolidated_Statements_of_Ope

Consolidated Statements of Operations And Other Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
License fee revenue	$8,454	$941	$4,276
Royalty revenue	36	0	0
Product sales	769	21	23
Contract service revenue	0	1,549	3,646
Total revenue	9,259	2,511	7,945
Cost of product sales	918	23	10
Cost of service revenue	0	2,608	4,230
Gross profit (loss)	8,341	-120	3,705
Operating expense (income)
Research and development	21,288	5,123	5,375
General and administrative	11,418	13,554	15,336
Gain on contract settlement	-910	-534	0
Recovery loss on sale of subsidiary	-50	-255	-250
Deconsolidation of former French Subsidiaries	-846	-641	0
Impairment on goodwill and intangible assets	0	0	8,254
Total operating expense	30,900	17,247	28,715
Loss from continuing operations before other income (expense)	-22,559	-17,367	-25,010
Other income (expense)
Interest expense, net	-339	-727	-325
Loss on extinguishment of debt	-82	0	0
Gain on sale of investment	0	2,600	0
Other income (expense), net	503	-376	175
Total other income (expense)	82	1,497	-150
Loss from continuing operations before income tax expense	-22,477	-15,870	-25,160
Income tax expense	0	0	-516
Loss from continuing operations	-22,477	-15,870	-25,676
Income (loss) from discontinued operations	691	-1,068	-6,095
Net loss	-21,786	-16,938	-31,771
Basic and diluted loss per common share
Loss per share from continuing operations (USD per share)	($0.57)	($0.46)	($0.94)
Income (loss) from discontinued operations (USD per share)	$0.02	($0.03)	($0.22)
Net loss per share (USD per share)	($0.55)	($0.49)	($1.16)
Weighted average common shares outstanding used for basic and diluted loss per share (shares)	39,540,409	34,413,253	27,458,184
Net loss	-21,786	-16,938	-31,771
Other comprehensive income
Foreign currency translation adjustments	0	0	641
Comprehensive loss	($21,786)	($16,938)	($31,130)

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities of continuing operations:
Net loss	($21,786)	($16,938)	($31,771)
Gain (loss) from discontinued operations	691	-1,068	-6,095
Loss (income) from continuing operations	-22,477	-15,870	-25,676
Adjustments to reconcile net loss from continuing operations to net cash used in operating activities of continuing operations:
Shares issued in connection with the fispemifene in-license agreement	5,904	0	0
Deconsolidation of former French Subsidiaries	-846	-641	0
Gain on contract settlement	-910	-534	0
Depreciation and amortization	170	77	203
Non cash interest expense	163	250	37
Loss on debt extinguishment	51	0	0
Stock-based compensation expense	1,731	1,992	2,917
Recovery on loss on sale of subsidiary	-50	-255	-250
Derivative liability revaluation	-517	274	0
Interest on contingent consideration	0	242	0
Non-cash deferred compensation	0	0	640
Impairment charges on property held for sale	0	0	656
Impairment charges on goodwill and intangible assets	0	0	8,254
Deferred tax provision	0	0	1,261
Other	0	131	0
Changes in operating assets and liabilities of continuing operations, net of assets and liabilities acquired and divested:
Accounts receivable	-620	253	682
Inventories	61	-341	0
Prepaid expenses and other current assets	-464	143	-928
Other assets	2	-52	0
Accounts payable	-66	-920	681
Deconsolidation of Former French Subsidiaries	-2,000	0	0
Accrued expenses	2,465	-476	-1,348
Accrued compensation	160	-140	967
Deferred revenue	-574	1,021	-490
Other liabilities	-214	-257	-3
Net cash used in operating activities from continuing operations	-18,031	-15,103	-12,397
Cash flows from investing activities of continuing operations:
Purchase of fixed assets	-580	-573	-436
Proceeds from sale of subsidiary	50	255	250
Proceeds from the sale of property and equipment	0	3,657	0
Deposit of restricted cash	0	-280	0
Cash acquired from acquisitions	0	0	2,067
Cash paid for acquisitions	0	0	-513
Net cash (used in) provided by investing activities from continuing operations	-530	3,059	1,368
Cash flows from financing activities of continuing operations:
Issuance of common stock, net of offering costs	5,913	16,612	20,410
Proceeds from issuance of notes payable, net	4,729	0	0
Proceeds from exercise of warrants	0	46	40
Payment under convertible notes	-2,750	0	-4,000
Release of restricted cash, net	42	0	0
Repurchase and retirement of stock	-42	0	0
Reissuance of convertible notes payable	0	0	3,413
Changes in derivative liability	0	0	906
Proceeds from the exercise of stock options	0	0	10
Repayment of capital lease obligations	-27	-27	-13
Net cash provided by financing activities from continuing operations	7,865	16,631	20,766
Cash flows from discontinued operations:
Net cash provided by (used in) operating activities of discontinued operations	16	38	-1,985
Net cash provided by (used in) investing activities of discontinued operations	675	1,650	-300
Net cash provided by (used in) discontinued operations	691	1,688	-2,285
Effect of exchange rate changes on cash	0	0	243
Net (decrease) increase in cash and cash equivalents	-10,005	6,275	7,695
Cash and cash equivalents, beginning of period	21,405	15,130	7,435
Cash and cash equivalents, end of period	11,400	21,405	15,130
Supplemental disclosure of cash flow information:
Cash paid for interest	193	238	318
Non-cash investing and financing activities:
Liability incurred in connection with fixed asset purchases	-7	0	0
Issuance of 193,798 common warrants to debtholders	104	0	0
Issuance of 486,923 shares of common stock upon conversion of convertible note	0	1,737	0
Release of restricted cash	0	-337	0
Release of obligations related to short-term loans	0	270	0
TopoTarget
Non-cash investing and financing activities:
Issuance of 688,717 shares of common stock to TopoTarget	0	1,543	0
Finesco
Non-cash investing and financing activities:
Issuance of shares of common stock	0	0	8,556
PediatRx Inc.
Non-cash investing and financing activities:
Issuance of shares of common stock	$0	$0	$1,000

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrants issued (in shares)	193,798
Issuance of shares of common stock upon conversion of convertible note	486,923
TopoTarget
Issuance of common stock upon acquisition, shares	688,717
Finesco
Issuance of common stock upon acquisition, shares		2,592,592
PediatRx Inc.
Issuance of common stock to PediatRx Inc. for co-promote agreement, shares		373,134

Consolidated_Statement_of_Chan

Consolidated Statement of Changes in Stockholders' Equity (USD $)	Total	Finesco	TopoTarget	Forendo Pharma Ltd.	Common Stock	Common Stock	Common Stock	Common Stock	Additional Paid-In Capital	Additional Paid-In Capital	Additional Paid-In Capital	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Accumulated Deficit
In Thousands, except Share data, unless otherwise specified						Finesco	TopoTarget	Forendo Pharma Ltd.		Finesco	TopoTarget	Forendo Pharma Ltd.
Beginning Balance at Dec. 31, 2011	$4,818				$21				$224,154				$0	($219,357)
Beginning Balance (shares) at Dec. 31, 2011					21,347,986
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (shares)					5,000
Issuance of common stock upon exercise of stock options	10								10
Issuance of stock to employees, consultants and Board of Director members (shares)					147,761
Issuance of stock to employees, consultants and Board of Director members	0
Stock-based compensation expense	2,917								2,917
Issuance of common stock for co-promote agreement (shares)					373,134
Issuance of common stock for co-promote agreement	1,000								1,000
Issuance of common stock, net of offering costs (shares)						2,592,592
Issuance of common stock and warrants, net of offering costs		8,556				3				8,553
Issuance of common stock and warrants, net of offering costs (shares)					5,453,601
Issuance of common stock and warrants, net of offering costs	20,410				6				20,404
Issuance of common stock upon exercise of warrants (shares)					17,595
Issuance of common stock upon exercise of warrants	40								40
Foreign currency translation adjustment	641												641
Net loss	-31,771													-31,771
Ending Balance at Dec. 31, 2012	6,621				30				257,078				641	-251,128
Ending Balance (shares) at Dec. 31, 2012					29,937,669
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock to employees, consultants and Board of Director members	0
Stock-based compensation expense	1,992								1,992
Issuance of common stock, net of offering costs (shares)					312,450		688,717
Issuance of common stock and warrants, net of offering costs	792		1,543				1		792		1,542
Issuance of common stock and warrants, net of offering costs (shares)					6,000,000
Issuance of common stock and warrants, net of offering costs	15,820				6				15,814
Issuance of common stock upon exercise of warrants (shares)					20,000
Issuance of common stock upon exercise of warrants	46								46
Issuance of restricted stock to employees and Board of Director members (shares)					95,645
Issuance of common stock upon exercise of convertible notes (shares)					486,923
Issuance of common stock upon exercise of convertible notes	1,737				1				1,736
Foreign currency translation adjustment	-641												-641
Net loss	-16,938													-16,938
Ending Balance at Dec. 31, 2013	10,972				38				279,000				0	-268,066
Ending Balance (shares) at Dec. 31, 2013					37,541,404
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (shares)	0
Issuance of stock to employees, consultants and Board of Director members	0
Stock-based compensation expense	1,731								1,731
Issuance of common stock, net of offering costs (shares)								3,600,070
Issuance of common stock and warrants, net of offering costs				5,904				3				5,901
Issuance of common stock and warrants, net of offering costs (shares)					3,570,030
Issuance of common stock and warrants, net of offering costs	6,050				3				6,047
Issuance of restricted stock to employees and Board of Director members (shares)					26,728
Repurchase and retirement of stock (shares)					-19,338
Repurchase and retirement of stock	-42								-42
Return of common stock in connection with contract settlement (shares)	-388,888				-388,888
Return of common stock in connection with contract settlement	-910								-910
Net loss	-21,786													-21,786
Ending Balance at Dec. 31, 2014	$1,919				$44				$291,727				$0	($289,852)
Ending Balance (shares) at Dec. 31, 2014					44,330,006

Organization_and_Summary_of_Si

Organization and Summary of Signifcant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Organization
	Apricus Biosciences, Inc. and Subsidiaries (“Apricus” or the “Company”) is a Nevada corporation initially formed in 1987. The Company has operated in the pharmaceutical industry since 1995 with a current primary focus on the development and commercialization of products and product candidates in the areas of specialty urology and rheumatology. The Company’s proprietary drug delivery technology is a permeation enhancer called NexACT® and the Company has one approved drug,Vitaros®, which uses the NexACT® delivery system, and is approved for the treatment of erectile dysfunction (“ED”) in Canada and through the European Decentralized Procedure (“DCP”) in Europe. Vitaros® was launched by the Company’s licensee partners in certain territories in Europe in the second half of 2014 and the Company expects that commercial launches will continue to occur throughout 2015. The Company has a second generation Vitaros® product candidate (“Room Temperature Vitaros®”) in development, which is a proprietary stabilized dosage formulation that is expected to be stored at room temperature conditions. RayVa™, the Company’s product candidate which also utilizes its proprietary permeation enhancer for the treatment of Raynaud’s Phenomenon secondary to scleroderma, received clearance from the United States Food and Drug Administration (“FDA”) in May 2014 to begin clinical studies, and the Company’s Phase 2a clinical trial began in December 2014.
	In October 2014, the Company entered into an agreement to license the exclusive United States development and commercialization rights for fispemifene, a tissue-specific selective estrogen receptor modulator (“SERM”) designed to treat secondary hypogonadism, chronic prostatitis and lower urinary tract symptoms in men (see note 3 for further details).
	Basis of Presentation and Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Certain prior year items have been reclassified to conform to the current year presentation.
	Use of Estimates
	The preparation of these consolidated financial statements in conformity with generally accepted accounting principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company’s most significant estimates relate to whether revenue recognition criteria have been met, accounting for clinical trials, the valuation of stock based compensation, the impairment of long-lived assets and valuation allowances for the Company’s deferred tax assets. The Company’s actual results may differ from these estimates under different assumptions or conditions.
	Liquidity
	The accompanying consolidated financial statements have been prepared on a basis that contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company had an accumulated deficit of approximately $289.9 million as of December 31, 2014, recorded a net loss of approximately $21.8 million for the year ended December 31, 2014 and has principally been financed through the sale of its common stock and other equity securities, debt financing and up-front payments received from commercial partners for the Company’s products under development. Funds raised in recent periods from the sale of common stock include approximately 1) $15.8 million from the Company’s May 2013 follow-on public offering, 2) $3.7 million in net proceeds during 2014 from the sale of common stock from its committed equity financing facility with Aspire Capital Fund, LLC (“Aspire Capital”) (see note 7 for further details) and 3) $2.2 million in net proceeds during 2014 from the sale of common stock via its “at-the-market” (“ATM”) stock selling facility, which was terminated in August 2014. These and other cash-generating activities should not necessarily be considered an indication of the Company’s ability to raise additional funds in the future.
	In February 2015, the Company entered into subscription agreements with certain purchasers pursuant to which it agreed to sell an aggregate of 6,043,955 shares of its common stock and issued warrants to purchase up to an additional 3,021,977 shares of its common stock.  Each share of common stock was priced at $1.82 and included one half of a warrant to purchase a share of common stock. The warrants have an exercise price of $1.82 per share, are exercisable beginning six months and one day after the date of issuance and expire on the seventh anniversary of the date of issuance. The total net proceeds from the offering were $10.8 million after deducting expenses of approximately $0.2 million. The subscription agreements require that the Company obtain permission from certain of the purchasers prior to selling shares under its committed equity financing facility.
	Based upon its current operating plan, the access to additional capital under its committed equity financing facility, potential to borrow an additional amount of up to $5.0 million under our credit facility, and the $10.8 million received from the Company’s February 2015 financing, the Company believes it has sufficient cash to fund its on-going operations through the first quarter of 2016.
	Based on its recurring losses, negative cash flows from operations and working capital levels, the Company will need to raise substantial additional funds to finance its operations. If the Company is unable to maintain sufficient financial resources, including by raising additional funds when needed, its business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that the Company will be able to obtain the needed financing on reasonable terms or at all. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company’s existing stockholders.
	Cash and Cash Equivalents
	Cash equivalents represent all highly liquid investments with an original maturity date of three months or less and were not significant as of December 31, 2014 and 2013.
	Restricted Cash
	Short term restricted cash of $0.3 million is primarily restricted cash held in escrow for environmental remediation services to be performed and for taxes in connection with the sale of our New Jersey facility, both of which are the obligation of the Company. The Company has recorded a liability for the environmental remediation as well as tax liabilities, both of which are included in accrued liabilities. These liabilities represent the best estimate of the fair value of the total obligations and are expected to be satisfied within the current year and are therefore classified as current restricted cash and current liabilities, respectively.
	Concentration of Credit Risk
	From time to time, the Company maintains cash in bank accounts that exceed the FDIC insured limits. The Company has not experienced any losses on its cash accounts. It performs credit evaluations of its customers, but generally does not require collateral to support accounts receivable. Laboratoires Majorelle, Recordati Ireland Ltd., and Hexal AG accounted for approximately 45%, 27%, and 27%, respectively, of total revenues during the year ended December 31, 2014. In addition, one of these companies comprised 75% of the Company’s accounts receivable as of December 31, 2014.
	Inventory Valuation
	Inventories are stated at the lower of cost or estimated realizable value. The Company capitalizes inventory costs associated with its products after regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes-down such inventories as appropriate. In addition, the Company’s products are subject to strict quality control and monitoring which is performed throughout the manufacturing process, which takes place at its contract manufacturer. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to cost of sales to write down such inventory to its estimated realizable value.
	Property and Equipment
	Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows:
	•	Machinery and equipment: three to five years
	•	Furniture and fixtures: ten years
	•	Computer software: five years
	Amortization of leasehold improvements and capital lease equipment is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term. The costs of additions and betterments are capitalized, and repairs and maintenance costs are charged to operations in the periods incurred (see note 5 for further details).
	Leases
	Leases are reviewed and classified as capital or operating at their inception. The Company records rent expense associated with operating leases on a straight-line basis over the term of the lease. The difference between rent payments and straight-line rent expense is recorded as deferred rent in accrued liabilities.
	Impairment of Long-Lived Assets
	The Company reviews for impairment of long-lived assets whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset.
	Debt Issuance Costs
	Amounts paid related to debt financing activities are capitalized and amortized over the term of the loan.
	Revenue Recognition
	The Company generates revenues from the licensing of technology rights and the sale of products, and historically, from the performance of pre-clinical testing services and contract sales services. Payments received under commercial arrangements, such as the licensing of technology rights, may include non-refundable fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products.
	The Company recognizes revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the Company’s price to the buyer is fixed or determinable; and (4) collectability is reasonably assured.
	License Fee Revenue
	Consideration received for the Company’s license arrangements may consist of non-refundable upfront license fees, various performance or sales milestones, royalties upon sales of product, and the delivery of product and/or research services to the licensor. The Company considers a variety of factors in determining the appropriate method of accounting under its license agreements, including whether the various elements can be separated and accounted for individually as separate units of accounting. Deliverables under the arrangement will be separate units of accounting, provided (i) a delivered item has value to the customer on a standalone basis; and (ii) if the arrangement includes a general right of return relative to the delivered item and delivery or performance of the undelivered item is considered probable and substantially in the Company’s control.
	The Company accounts for revenue arrangements with multiple elements by separating and allocating consideration in a multiple-element arrangement according to the relative selling price of each deliverable. If an element can be separated, an amount is allocated based upon the relative selling price of each element. The Company determines the relative selling price of a separate deliverable using the price it charges other customers when it sells that product or service separately; however, if the product or service is not sold separately and third party pricing evidence is not available, the Company will use its best estimate of selling price.
	The Company defers recognition of non-refundable upfront fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent of its performance under the other elements of the arrangement. Non-refundable, up-front fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on its part are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered. The specific methodology for the recognition of the revenue is determined on a case-by-case basis according to the facts and circumstances of the applicable agreement.
	Product Sales Revenue
	The Company has supply and manufacturing agreements with certain of its licensee partners for the manufacture and delivery of Vitaros® product. These agreements do not permit the Company’s licensee partners to return product, unless the product sold to the licensee partner is short-dated as defined in each respective license agreement. In those cases, the Company defers revenue recognition on these shipments until the right of return no longer exists, which is the earlier of: (i) evidence that the product has been sold through to the end customer or (ii) the right of return expires. As such, the Company does not have a sales and returns allowance recorded as of December 31, 2014.
	In 2014, the Company commenced shipping of its Vitaros® product to its licensee partners and recognized product sales revenue on certain of these shipments since the criteria for revenue recognition was met.
	Royalty Revenue
	The Company relies on its commercial partners to sell its product, Vitaros®, in approved markets. The Company receives royalties from licensee partners based upon the amount of sales of licensed Vitaros® product consummated by its commercial partners. Royalty revenues are computed based on sales reported to the Company by its licensee partners on a quarterly basis and agreed upon royalty rates for the respective license agreement.
	Contract Service Revenue
	Revenue from contract sales services resulted primarily from the Company’s former subsidiaries, Scomedica SAS, NexMed Europe SAS and NexMed Pharma SAS (the “French Subsidiaries”). The revenue was based on the number of medical visits plus an incentive based on the sales growth of the targeted pharmaceutical products. Revenue associated with medical visits was recognized in the accounting period in which services were rendered. For research services, the Company determined the period in which the performance obligation occurred and recognized revenue using the proportional performance method when the level of effort to complete its performance obligations under an arrangement was able to be reasonably estimated. The Company does not anticipate future revenues from contract services.
	Cost of Product Sales
	The Company’s cost of product sales includes direct material and manufacturing overhead associated with the production of inventories. Cost of product sales is also affected by manufacturing efficiencies, allowances for scrap or expired material and additional costs related to initial production quantities of new products.
	Deferred Cost of Product Sales
	Deferred cost of product sales is stated at the lower of cost or net realizable value and includes product sold where title has transferred, but the criteria for revenue recognition have not been met. The Company’s deferred cost of product sales is included in prepaid expenses and other current assets in the consolidated balance sheets.
	Research and Development
	Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company’s behalf, pursuant to development and consulting agreements in place.
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.
	The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition.
	Loss per Common Share
	Basic and diluted net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding for the respective period, without consideration of common stock equivalents as they would have an anti-dilutive effect on per share amounts.
	The following securities that could potentially decrease net loss per share in the future are not included in the determination of diluted loss per share as they are anti-dilutive and are as follows:
			Year Ended December 31,
			2014		2013			2012
	Outstanding stock options		3,955,548		2,351,237			2,213,916
	Outstanding warrants		6,859,682		6,185,492			3,205,492
	Unvested restricted stock		—		26,728			112,705
Convertible notes payable		—		1,065,891			1,544,402
		10,815,230		9,629,348			7,076,515
Stock-Based Compensation
The estimated grant date fair value of stock options granted to employees and directors is calculated based upon the closing stock price of the Company’s common stock on the date of the grant and recognized as stock-based compensation expense over the expected service period. The Company estimates the fair value of each option award on the date of grant using the Black-Scholes option pricing model.
Segment Information
The Company operates under one segment which develops pharmaceutical products.
Geographic Information
Revenues by geographic area for the Company’s continuing operations are as follows (in thousands):
		Year Ended December 31,
		2014			2013			2012
France		$	4,150		$	921		$	2,970
Europe- Other		5,109			1,590			2,475
North America		—			—			2,500
		$	9,259		$	2,511		$	7,945
-1	Amounts included in Europe-other have not been broken out by country as it is impractical to do so given the nature and structure of the license agreements which cover multiple territories. See note 2 for further details related to these agreements.
All of the Company’s net long-lived assets were located in the United States in 2014 and 2013.
Recent Accounting Pronouncements
In November 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity. This update clarifies how current guidance should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, it clarifies that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting the new standard should be applied on a modified retrospective basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company is currently in the process of evaluating whether the adoption of this update will have a material effect on its consolidated financial statements and related disclosures.
In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements -Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this update will require management to assess, at each annual and interim reporting period, the entity’s ability to continue as a going concern and, if management identifies conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued, to disclose in the notes to the entity’s financial statements the principal conditions or events that raised substantial doubt about the entity’s ability to continue as a going concern, management’s evaluation of their significance, and management’s plans that alleviated or are intended to alleviate substantial doubt about the entity’s ability to continue as a going concern. This new standard is effective for annual periods ending after December 15, 2016 and early application is permitted. The Company is currently in the process of evaluating whether the adoption of this update will have a material effect on its consolidated financial statements and related disclosures.
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires entities to recognize revenue in the way it expects to be entitled for the transfer of promised goods or services to customers. This pronouncement is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the effect that this pronouncement will have on its financial statements and related disclosures.
In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. This ASU raises the threshold for a disposal to qualify as discontinued operations and requires new disclosures for individually material disposal transactions that do not meet the definition of a discontinued operation. Under the new standard, companies report discontinued operations when they have a disposal that represents a strategic shift that has or will have a major impact on operations or financial results. This update will be applied prospectively and is effective for annual periods, and interim periods within those years, beginning after December 15, 2014. Early adoption is permitted provided the disposal was not previously disclosed. This update will not have a material impact on the Company's reported results of operations and financial position.

Vitaros_Licensing_Agreements

Vitaros Licensing Agreements	12 Months Ended
	Dec. 31, 2014
Disclosure - Licensing and Research and Development Agreements [Abstract]
Vitaros Licensing Agreements	VITAROS® LICENSING AGREEMENTS
	Abbott Laboratories Limited
	In January 2012, the Company entered into a license agreement with Abbott Laboratories Limited (“Abbott”), granting Abbott the exclusive rights to commercialize Vitaros® for the treatment of ED in Canada. The product was approved by Health Canada in late 2010. To date, the Company has received $2.5 million in upfront payments and is eligible to receive an additional $13.2 million in aggregate regulatory and sales milestone payments, plus tiered royalty payments based on Abbott’s sales of the product.
	Bracco SpA
	In December  2010, the Company entered into a license agreement with Bracco SpA (“Bracco”), granting Bracco the exclusive rights to commercialize Vitaros® for the treatment of ED in Italy. Vitaros® was granted national phase approval for the treatment of ED in Italy in November 2013. To date, the Company has received $1.3 million in upfront payments and regulatory milestones and is eligible to receive up to an additional €4.5 million ($5.5 million as of December 31, 2014) in regulatory and sales milestone payments, plus tiered double-digit royalties based on Bracco’s sales of the product.
	Hexal AG, an affiliate within the Sandoz Division of the Novartis Group of Companies
	In February 2012, the Company entered into a license agreement with Hexal AG, an affiliate within the Sandoz Division of the Novartis Group of Companies (“Sandoz”), granting Sandoz the exclusive rights to commercialize Vitaros® for the treatment of ED in Germany. In December 2013, the Company amended and restated its license agreement with Sandoz to include the following countries as part of the exclusive license agreement: Austria, Belgium, Denmark, Finland, Iceland, Luxemburg, the Netherlands, Norway, Sweden and Switzerland (the “Expanded Territory”). In June 2014, the Company entered into a Manufacturing and Supply Agreement with Sandoz whereby the Company’s or its contract manufacturer will manufacture Vitaros® product and supply the product to Sandoz on a cost plus basis. Vitaros® has been granted national phase approval for the treatment of ED in Germany, the Netherlands, Sweden, Belgium, and Luxembourg. The Company filed a marketing application in Switzerland with Swissmedic, the Swiss Agency for Therapeutic Products, for Vitaros® for the treatment of ED and is awaiting regulatory comments from Swissmedic.
	In December 2013, upon amendment, the Company recorded $2.0 million of deferred revenue for the upfront payment received since Sandoz was entitled to a $2.0 million refund if certain regulatory and manufacturing conditions were not met. In December 2014, the Company met the manufacturing requirement and recognized $1.0 million of the upfront payment as license fee revenue during the fourth quarter of 2014. The results of the regulatory condition will be determined by December 2016.
	In 2014, Sandoz launched Vitaros® in Germany, Sweden and Belgium. The Company recorded $1.0 million in aggregate license fee revenue in 2014 as a result of the launches in Sweden and Belgium in August 2014 and November 2014, respectively.
	To date, the Company has received $4.0 million in upfront payments and launch milestone payments and is eligible to receive up to €0.2 million ($0.2 million as of December 31, 2014) in regulatory milestones, up to $1.5 million in marketing launch milestones, and up to €41.75 million ($50.7 million as of December 31, 2014) in sales milestones. Additionally, the Company is entitled to receive tiered double-digit royalties on Sandoz’ sales of the product.
	In February 2015, the Company amended its license agreement with Sandoz to grant exclusive rights to commercialize Vitaros® in the following countries: Malaysia, Indonesia, the Philippines, Thailand, Taiwan, Vietnam, Hong Kong and Singapore (the “Expanded APAC Territory”). Under the amended agreement, the Company earned an upfront payment of $0.4 million and is entitled to receive an additional regulatory milestone payment of $0.1 million upon marketing authorization in the Expanded APAC Territory as well as tiered double-digit royalties based on Sandoz’ sales of the product.
	Laboratoires Majorelle
	In November 2013, the Company entered into a license agreement with Laboratoires Majorelle (“Majorelle”), granting Majorelle the exclusive rights to market Vitaros® for the treatment of ED in France, Monaco and certain countries in Africa. In December 2013, in a related negotiation, Majorelle agreed to make severance payments to certain former employees of the Company’s former French Subsidiaries for an aggregate amount of approximately $2.0 million on behalf of the Company. In September 2014, the Company entered into a Manufacturing and Supply Agreement with Majorelle whereby the Company’s or its contract manufacturer will manufacture Vitaros® product and supply the product to Majorelle on a cost plus basis. In addition, during the first quarter of 2015, Groupe Parima began manufacturing product for Majorelle under its own manufacturing and supply agreement. Vitaros® was granted national phase approval for the treatment of ED in France in December 2013.
	The Company concluded that the fair value of the Vitaros® license granted was equal to $4.0 million or the sum of the $1.8 million upfront payment received, the $0.2 million payment received for National Phase approval in France, and the $2.0 million paid by Majorelle on behalf of the Company. During the second quarter of 2014, upon withdrawal of the Works Council Claim in June 2014 (see note 4 for further details regarding the claim), the Company recognized $3.0 million of the $4.0 million Vitaros® license fair value as license fee revenue in its statement of operations. During the third quarter of 2014, the Company met the remaining contractual condition to deliver a specified amount of Vitaros® and therefore, the remaining $1.0 million of deferred revenue that had previously been deferred was recognized as license fee revenue in the Company’s consolidated statement of operations. To date, the Company has received $2.0 million in upfront payments and regulatory milestones, and is eligible to receive up to $2.0 million in additional regulatory milestone payments and €15.5 million ($18.8 million as of December 31, 2014) in sales milestones, plus tiered double-digit royalties based on Majorelle’s sales of the product.
	Recordati Ireland Ltd.
	In February 2014, the Company entered into a license agreement with Recordati Ireland Ltd. (“Recordati”), granting Recordati the exclusive rights to market Vitaros® for the treatment of ED in Spain, Ireland, Portugal, Greece, Cyprus, the CEE Countries (Central and Eastern Europe), Russia and the other CIS Countries (former Soviet Republics), Ukraine, Georgia, Turkey and certain countries in Africa. In June 2014, the Company entered into a Manufacturing and Supply Agreement with Recordati whereby the Company or its contract manufacturer will manufacture Vitaros® product and supply the product to Recordati on a cost plus basis. Vitaros® has been granted national phase approval for the treatment of ED in Ireland and Spain.
	The Company received $2.5 million in upfront payments in February 2014 which were recorded as deferred revenue. Upon execution of the manufacturing and supply agreement in June 2014, the Company recorded the deferred revenue as license fee revenue of $2.5 million. To date, the Company has received $2.5 million in upfront payments and is eligible to receive up to €1.0 million ($1.2 million as of December 31, 2014) in commercial launch payments and €34.5 million ($41.9 million as of December 31, 2014) in sales milestones. Additionally, the Company is entitled to receive tiered double-digit royalties based on Recordati’s sales of the product.
	Takeda Pharmaceuticals International GmbH
	In September 2012, the Company entered into a license agreement with Takeda Pharmaceuticals International GmbH (“Takeda”), granting Takeda the exclusive rights to market Vitaros® for the treatment of ED in the United Kingdom. In September 2013, the Company entered into a Manufacturing and Supply Agreement with Takeda whereby the Company or its contract manufacturer will manufacture Vitaros® product and supply the product to Takeda on a cost plus basis. Vitaros® was granted national phase approval in August 2013 for the treatment of ED in the UK. To date, the Company has received $1.0 million in upfront payments and is eligible to receive up to €34.65 million ($42.1 million as of December 31, 2014) in up-front license fees and aggregate milestone payments plus tiered double-digit royalty payments. Takeda launched Vitaros® in the United Kingdom in June 2014.
	Actavis plc
	Warner Chilcott Company, Inc., now a subsidiary of Actavis plc, acquired the Vitaros® United States commercial rights in 2009. To date, the Company has received $2.5 million in upfront payments and is eligible to receive an additional $2.5 million upon receipt of an NDA approval from the FDA.

InLicensing_Agreement_Notes

In-Licensing Agreement (Notes)	12 Months Ended
	Dec. 31, 2014
In-Licensing Agreement [Abstract]
In-Licensing Agreement	IN-LICENSING AGREEMENT
	On October 17, 2014, the Company entered into a license agreement and stock issuance agreement with Forendo Pharma Ltd. (“Forendo”), under which the Company was granted exclusive rights in the United States to develop and commercialize fispemifene, a tissue-specific SERM designed to treat secondary hypogonadism, chronic prostatitis and lower urinary tract symptoms in men.
	In exchange for the license, the Company issued to Forendo approximately 3.6 million shares of common stock with a value of $5.9 million based on the Company’s closing stock price on the date of the agreement and made an upfront cash payment of $5.0 million. Additionally, the Company may be obligated to pay Forendo up to $45.0 million based on completion of certain regulatory milestones, up to $260.0 million in sales milestones, plus tiered double-digit royalties based on its sales of the product in the United States.
	As part of the agreement, the Company is obligated to pay Forendo $2.5 million upon the earlier of 1) initiation of a Phase 2b clinical trial or 2) April 1, 2015. Since the agreement is not terminable prior to payment, the payment was considered deferred consideration and was recorded as a liability as of December 31, 2014.
	The Company recognized research and development expense of $13.6 million upon the completion of the transaction. The $13.6 million is the sum of the following: $5.0 million upfront payment made in October 2014; $5.9 million in common stock issued to Forendo; the additional $2.5 million cash consideration due no later than April 1, 2015, and transaction costs of $0.2 million.

Ceased_and_Discontinued_Operat

Ceased and Discontinued Operations	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Ceased and Discontinued Operations	CEASED AND DISCONTINUED OPERATIONS
	In June 2014, consistent with the Global Settlement Agreement (“GSA”) signed in February 2014, the Works Council withdrew its previously submitted €4.1 million claim in the Versailles Civil Court (the “Civil Court”), all parties accepted the withdrawal and the Civil Court judge closed the discussions between all parties. The final procedural step occurred in October 2014, when the Company received a written judgment from the Civil Court acknowledging the dismissal of the claim and the closure of the litigation. Given the existence of the aforementioned ratified GSA, the accepted withdrawal and the closure of the discussions by the Civil Court judge, it was concluded during the second quarter of 2014 that the Company was relieved of all claims previously asserted by the French Works Council.
	Pursuant to the aforementioned license and settlement agreements, Majorelle agreed to make certain severance payments of approximately $2.0 million to the former French Subsidiaries’ employees on behalf of the Company, a portion of which were made in May 2014. In addition, the Works Council and the Judicial Liquidator and Trustee of the Company’s former French Subsidiaries as well as each of the former French Subsidiaries’ employees, waived all claims they had asserted or could have asserted against the Company related to the liquidation and reorganization of the French Subsidiaries. As a result, during the second quarter of 2014, the Company released the approximate $2.8 million liability previously recorded in connection with the deconsolidation of the former French Subsidiaries and recognized approximately $0.8 million as a gain on deconsolidation as follows:
	Release of deconsolidation liability	$	2.8
	Less: Payments made by Majorelle on the Company’s behalf	(2.0		)
	Gain on deconsolidation of former French Subsidiaries	$	0.8
	Sale of Bio-Quant
	In June 2014, the Company and BioTox amended its stock purchase agreement and the Company received a one-time cash payment of approximately $0.6 million in exchange for relinquishing its rights to minimum payments in the future. Prior to the amendment of the agreement, the Company also received payments of approximately $0.1 million for a total received from BioTox of $0.7 million in 2014. The Company has rights to certain potential future payments upon a change of control of BioTox within a specified time frame. These potential future payments will be recorded if and when realized.
	The Company has recorded the gain of approximately $0.7 million as discontinued operations within its statement of operations in 2014. Historically, the Company reflected the operations and subsequent cash collections associated with the sale of the business as a component of continuing operations, on the line recovery on sale of subsidiary within the consolidated statements of operations. However, the Company has elected not to correct these prior period amounts which were deemed not material to prior period financial statements.

Other_Financial_Information

Other Financial Information	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other Financial Information	OTHER FINANCIAL INFORMATION
	Inventory
	Inventory is comprised of the following (in thousands):
		December 31,
		2014			2013
	Raw materials	$	106		$	209
	Work in process	169			127
	Inventory	$	275		$	336
	Property and Equipment
	Property and equipment are comprised of the following (in thousands):
		December 31,
		2014			2013
	Leasehold improvements	$	43		$	20
	Machinery and equipment	1,385			847
	Capital lease equipment	76			76
	Computer software	142			134
	Furniture and fixtures	37			34
	Total property and equipment	1,683			1,111
	Less: accumulated depreciation and amortization	(325		)	(156		)
	Property and equipment, net	$	1,358		$	955
	Depreciation expense totaled $0.2 million, $0.1 million and $0.2 million for the years ended December 31, 2014, 2013, and 2012, respectively.
	Accrued Expenses
	Accrued expenses are comprised of the following (in thousands):
		December 31,
		2014			2013
	Deferred consideration to Forendo (Note 3)	$	2,500		$	—
	Outside research and development services	838			298
	Professional fees	625			997
	Deferred compensation	176			184
	Environmental remediation	126			168
	Other	290			472
		$	4,555		$	2,119
	Other Long Term Liabilities
	Other long term liabilities are comprised of the following (in thousands):
		December 31,
		2014			2013
	Deferred compensation	$	312		$	487
	Deferred rent	41			80
	Capital lease payable	5			11
		$	358		$	578
	In 2002, the Company entered into an employment agreement with Y. Joseph Mo, Ph.D., pursuant to which Dr. Mo served as the Company’s Chief Executive Officer and President. Under the employment agreement, Dr. Mo was entitled to severance, payable monthly for 180 months, upon termination of his employment. Dr. Mo’s employment was terminated in December 2005. In addition to the long-term portion above, the Company had a balance of $0.2 million classified as short-term deferred severance compensation as of December 31, 2014 and December 31, 2013.
	Gain on Contract Settlement
	The $0.9 million gain on contract settlement recorded during 2014 represents the fair value of 388,888 escrowed shares of common stock that were returned to the Company in connection with a settlement with former managers of the French Subsidiaries. These shares were restored as authorized, unissued common stock in March 2014. The $0.5 million gain on contract settlement recorded during 2013 represents the difference between the $1.2 million in common shares issued to TopoTarget in exchange for the extinguishment of $1.7 million of contingent consideration.

Debt

Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt	DEBT
	Credit Facility
	On October 17, 2014 (the “closing date”), the Company entered into a loan and security agreement (the “credit facility”) with Oxford Finance LLC (“Oxford”) and Silicon Valley Bank (“SVB”) (the “lenders”), pursuant to which the lenders agreed to make term loans totaling up to $10.0 million available to the Company. The proceeds from these loans are designated to pay off existing indebtedness and for working capital and general business purposes. The first $5.0 million term loan was funded on the closing date of the credit facility. A second term loan of up to a principal amount of $5.0 million may be funded at the Company’s request prior to April 30, 2015, subject to certain conditions. The lenders have first priority over all other potential creditors. Substantially all of the Company’s current and future assets, other than intellectual property, have been pledged as collateral. The lenders have the right to declare the loan immediately due and payable in an event of default under the credit facility, which includes, among other things, a material adverse change in the Company’s business, operations, or financial condition or a material impairment in the prospect of repayment of the loan. As of December 31, 2014, the Company was in compliance with all covenants under the credit facility.
	The first term loan bears interest at an annual rate of 7.95%. The repayment schedule provides for interest-only payments in arrears for the first 12 months followed by consecutive equal monthly payments of principal and interest in arrears through the maturity date, or October 1, 2018. The Company has the option to prepay the outstanding balance of the term loan in full prior to the maturity date, subject to a prepayment fee of up to 3%. Upon repayment of each term loan, the Company is also required to make a final payment to the lenders equal to 6.00% of the original principal amount of each term loan funded. This final payment is being accreted over the life of the credit facility using the effective interest method.
	On the closing date of the credit facility, the Company issued to Oxford and SVB warrants to purchase up to 193,798 shares of common stock at an exercise price of $1.29 per share. The warrants expire ten years from the date of issuance. The initial fair value of the warrants was recorded as a discount to the principal balance and is being amortized over the life of the credit facility using the effective interest method.
	The Company’s notes payable balance as of December 31, 2014 consisted of the following (in thousands):
	Notes payable	$	5,000
	Add: accretion of final payment fee	16
	Less: unamortized debt discount	(237		)
		4,779
	Less: current portion of notes payable, net	(153		)
		$	4,626
	The debt issuance costs, accretion of the final payment and amortization of the warrants are included in interest expense in the Company’s consolidated financial statements. The Company recognized interest expense related to the credit facility of $0.1 million during the year ended December 31, 2014.
	Convertible Notes Payable
	On October 17, 2014, the Company amended the terms of its 7% Convertible Notes (“2012 Convertible Notes”) due December 31, 2014 and repaid the remaining aggregate principal balance of $1.225 million with accrued interest. In addition, the Company issued warrants to the former note holders for the right to purchase up to an aggregate of 480,392 shares of common stock, at an exercise price of $2.55 per share. The warrants are exercisable through December 31, 2015. The Company incurred a loss on extinguishment of debt of approximately $0.1 million during the fourth quarter of 2014, which consisted of the fair value of the warrants, an additional payment to the note holders in the amount of the remaining interest payments prior to the amendment, the write-off of the remaining debt discount, and legal fees incurred as part of the amended terms.
	The Company’s convertible notes payable balance as of December 31, 2013 consisted of the following (in thousands):
	Convertible notes payable	$	4,000
	Less: conversions to common stock	(1,250		)
		2,750
	Less: unamortized debt discount	(150		)
		$	2,600
	The Company recognized interest expense related to its convertible notes payable of $0.2 million, $0.5 million and $0.3 million during the years ended December 31, 2014, 2013 and 2012, respectively.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholder's Equity	STOCKHOLDERS' EQUITY
	Preferred Stock
	The Company is authorized to issue 10.0 million shares of preferred stock, par value $0.001, of which 1.0 million shares are designated as Series A Junior Participating Preferred Stock, 800 are designated as Series B 8% Cumulative Convertible Preferred Stock, 600 are designated as Series C 6% Cumulative Convertible Preferred Stock and 50,000 have been designated as Series D Junior Participating Cumulative Preferred Stock. No shares of preferred stock were outstanding as of December 31, 2014 or 2013.
	Common Stock Offerings
	Ascendiant Offering Agreement
	During 2014, 2013 and 2012, the Company sold an aggregate of 954,922, 312,450, and 515,329 shares of common stock, respectively, under the Ascendiant Offering Agreement resulting in offering proceeds of approximately $2.2 million, $0.8 million, and $2.0 million, respectively. The agreement with Ascendiant was terminated by the Company in August 2014.
	Aspire Common Stock Purchase Agreement
	In August 2014, the Company and Aspire Capital entered into a Common Stock Purchase Agreement (the “Aspire Purchase Agreement”), which provides that Aspire Capital is committed to purchase, if the Company chooses to sell and at the Company’s discretion (pursuant to obtaining the permission mentioned in the paragraph below), an aggregate of up to $22.0 million of shares of the Company’s common stock over the 24-month term of the Aspire Purchase Agreement. The Aspire Purchase Agreement can be terminated at any time by the Company by delivering notice to Aspire Capital. The shares will be sold at a price equal to the lower of the lowest sales price of the Company’ s common stock on the purchase date or the average of the lowest three closing sales prices for the twelve business days prior to the purchase date. Under the Aspire Purchase Agreement, the Company delivered to Aspire Capital a commitment fee in the form of common stock of 255,161 shares at a value of $0.4 million, in consideration for Aspire Capital's obligation to purchase up to $22.0 million of the Company’s common stock. During 2014, the Company sold approximately 2.4 million additional shares of its common stock to Aspire Capital at a weighted average sales price of $1.62 per share, for aggregate net proceeds of $3.7 million. As of December 31, 2014, the Company had $18.2 million remaining under the terms of the Aspire Purchase Agreement.
	February 2015 Financing
	In February 2015, the Company entered into subscription agreements with certain purchasers pursuant to which it agreed to sell an aggregate of 6,043,955 shares of its common stock and issued warrants to purchase up to an additional 3,021,977 shares of its common stock.  Each share of common stock was priced at $1.82 per unit and included one half of a warrant to purchase a share of common stock. The warrants have an exercise price of $1.82 per share, are exercisable beginning six months and one day after the date of issuance and expire on the seventh anniversary of the date of issuance. The total net proceeds from the offering were $10.8 million after deducting expenses of approximately $0.2 million. The subscription agreements also require that the Company obtain permission from certain of the purchasers of the subscription agreements prior to selling shares under its committed equity financing facility.
	Warrants
	A summary of warrant activity during the year ended December 31, 2014 is as follows:
		Common Shares		Weighted			Weighted
		Issuable upon		Average			Average
		Exercise		Exercise			Remaining
				Price			Contractual
							Life (in years)
	Outstanding at December 31, 2013	6,185,492		$	4.01		3.6
	Issued	674,190		2.19
	Exercised	—		—
	Cancelled	—		—
	Outstanding at December 31, 2014	6,859,682		3.83			2.7
	Exercisable at December 31, 2014	6,859,682		$	3.83		2.7
	During the years ended December 31, 2013, and 2012, the Company received proceeds of $50,000 and $40,000 from the exercise of 20,000, and 17,595 warrants, respectively.
	In connection with the credit facility entered into in October 2014, the Company issued warrants to the lenders to purchase up to 193,798 shares of common stock at an exercise price of $1.29 per share. The warrants expire ten years from each date of issuance. The Company also issued warrants to its former convertible note holders to purchase up to an aggregate of 480,392 shares of common stock at an exercise price of $2.55 per share. The warrants are exercisable through December 31, 2015 (see note 6 for further details regarding the warrants issued in connection with the debt arrangements).
	The following table shows the number of outstanding warrants by exercise price and date of expiration as of December 31, 2014:
	Shares Issuable Upon Exercise		Exercise Price			Expiration Date
	716,356		$	2.27		Oct-15
	480,392		$	2.55		Dec-15
	2,469,136		$	5.25		Feb-17
	3,000,000		$	3.4		May-18
	193,798		$	1.29		Jan-24
	6,859,682

Equity_Compensation_Plans

Equity Compensation Plans	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Compensation Plans	EQUITY COMPENSATION PLANS
	As of December 31, 2014, the Company had two share-based compensation plans: the 2012 Stock Long Term Incentive Plan (the “2012 Plan”) and the NexMed, Inc. 2006 Stock Incentive Plan (“the 2006 Plan”). Both plans provide for the issuance of incentive and non-incentive stock options, restricted and unrestricted stock awards, stock unit awards and stock appreciation rights. Options granted generally vest over a period of one to four years and have a maximum term of 10 years from the date of grant. As of December 31, 2014, an aggregate of 6.8 million shares of common stock are authorized under the Company’s equity compensation plans, of which 1.6 million common shares are available for future grants.
	Stock Options
	A summary of stock option activity during the year ended December 31, 2014 is as follows:
		Number of			Weighted				Weighted		Total
		Shares			Average				Average Remaining		Aggregate
					Exercise				Contractual		Intrinsic
					Price				Life (in years)		Value
	Outstanding as of December 31, 2013	2,351,237			$	3.1			8.6		$	444,012
	Granted	2,173,506			1.96
	Exercised	—			—
	Cancelled	(569,195	)		2.37
	Outstanding as of December 31, 2014	3,955,548			$	2.58			7.5		$	—
	Vested or expected to vest as of December 31, 2014	3,837,625			$	2.61			7.4		$	—
	Exercisable as of December 31, 2014	1,613,222			$	3.42			5.1		$	—
	As of December 31, 2014, 2013, and 2012, there were 1,613,222, 752,815 and 856,868 options exercisable, respectively. The aggregate intrinsic value of options exercised during the years ended December 31, 2012 was approximately $16,000.
	Stock Awards
	A summary of stock award activity during the year ended December 31, 2014 is as follows:
		Number of			Weighted Average
		Shares			Grant Date Fair Value Per Share
	Nonvested as of December 31, 2013	26,728			$	4.58
	Granted	—			—
	Vested	(26,728	)		4.58
	Forfeited	—			—
	Nonvested as of December 31, 2014	—			$	—
	Share-Based Compensation
	The value of stock grants is calculated based upon the closing stock price of the Company’s common stock on the date of the grant. For stock options granted to employees and directors, the Company recognizes compensation expense based on the grant-date fair value over the requisite service period of the awards, which is the vesting period. The Company estimates the fair value of each option award on the date of grant using the Black-Scholes option pricing model.
	The following table presents the weighted average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option-pricing model, as well as the resulting weighted average fair values:
		Year Ended December 31,
		2014				2013				2012
	Risk-free interest rate	1.58% - 1.96%				1.08% - 1.85%				0.6% - 1.1%
	Volatility	80.75		%		70		%		70		%
	Dividend yield	0		%		0		%		0		%
	Expected term	5.25- 6.08 years				5.25-6.25 years				5.25-6.0 years
	Forfeiture rate	3.6		%		2.66		%		2.66		%
	Weighted average fair value	$	1.25			$	1.52			$	1.95
	Expected Volatility. The Company uses analysis of historical volatility to compute the expected volatility of its stock options.
	Expected Term. The expected life assumptions are based on the simplified method set forth in SEC’s Staff Accounting Bulletin 14.
	Risk-Free Interest Rate. The interest rate used in valuing awards is based on the yield at the time of grant of a United States Treasury security with an equivalent remaining term.
	Dividend Yield. The Company has never paid cash dividends, and does not currently intend to pay cash dividends, and thus has assumed a 0% dividend yield.
	Pre-Vesting Forfeitures. Estimates of pre-vesting option forfeitures are based on the Company’s experience. The Company adjusts its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment in the period of change and also impact the amount of compensation expense to be recognized in future periods. Adjustments have not been significant to date.
	As of December 31, 2014, there was $2.7 million in unrecognized compensation cost related to non-vested stock options expected to be recognized over a weighted average period of 2.9 years.
	The value of stock awards is calculated based upon the closing stock price of the Company’s common stock on the date of the grant and is expensed over the vesting period of the award. As of December 31, 2014 there are no non-vested stock awards outstanding and therefore no unrecognized compensation cost related to non-vested restricted stock.
	The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company’s consolidated statements of operations (in thousands):
			Year Ended December 31,
			2014				2013				2012
	Research and development		$	267			$	225			$	299
	General and administrative		1,464				1,767				2,618
			$	1,731			$	1,992			$	2,917

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES
	The Company has incurred losses since inception, which have generated United States net operating loss carry forwards (“NOLs”) of approximately $174.7 million for federal income tax purposes. These carry forwards are available to offset future taxable income and expire beginning in 2018 through 2034 for federal income tax purposes.
	Utilization of the NOLs may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required under Internal Revenue Code Section 382 (“Section 382”), as well as similar state and foreign provisions. These ownership changes may limit the amount of NOLs that can be utilized annually to offset future taxable income. In general, an “ownership change” as defined by Section 382 results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Since the Company’s formation, the Company has raised capital through the issuance of capital stock on several occasions which, combined with the purchasing stockholders’ subsequent disposition of those shares, may have resulted in such an ownership change, or could result in an ownership change in the future upon subsequent disposition.
	The Company has not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company’s formation due to the complexity and cost associated with such a study, and the fact that there may be additional such ownership changes in the future. If the Company has experienced an ownership change at any time since its formation, utilization of the NOLs would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOL before utilization. Further, until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit under authoritative accounting guidance. Any NOLs that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance with no net effect on income tax expense or the effective tax rate.
	Details of income tax expense are as follows (in thousands):
		December 31,
		2014				2013				2012
	Current
	Federal	$	—			$	—			$	—
	State	—				—				—
	Foreign	—				—				—
	Total current	—				—				—
	Deferred
	Federal	—				—				—
	State	—				—				—
	Foreign	—				—				516
	Total deferred	—				—				516
	Total income tax expense	$	—			$	—			$	516
	Deferred tax assets consist of the following:
		December 31,
		2014				2013
	Net operating tax loss carryforwards	$	60,380			$	59,927
	Research and development tax credits	534				404
	Deferred compensation	168				269
	Other accruals and reserves	670				504
	Basis of intangible assets	4,610				(45		)
	Total deferred tax asset	66,362				61,059
	Less valuation allowance	(66,362		)		(61,059		)
	Net deferred tax asset	$	—			$	—
	The net operating loss carryforwards and tax credit carryforwards resulted in a noncurrent deferred tax asset as of December 31, 2014 and 2013 of approximately $60.9 million and $60.3 million, respectively. In consideration of the Company’s accumulated losses and the uncertainty of its ability to utilize this deferred tax asset in the future, the Company has recorded a full valuation allowance as of such dates.
	The Company follows the provisions of income tax guidance which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. The guidance requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax positions that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company’s Federal income tax returns for 2011 to 2014 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years. Unrecognized tax benefits, if recognized, would have no effect on the Company’s effective tax rate. The Company’s policy is to recognize interest and penalties related to unrecognized tax benefits in income tax expense. As of December 31, 2014, the Company has not recorded any interest and penalties related to uncertain tax positions. The Company does not foresee any material changes to unrecognized tax benefits within the next twelve months.
	A reconciliation of the Company’s unrecognized tax benefits from January 1, 2014 through December 31, 2014 is provided in the following table (in thousands):
		Year Ended December 31,
		2014				2013
	Beginning balance	$	2,795			$	2,879
	Increase in current period positions	34				41
	Decrease in prior period positions	(7		)		(125		)
	Ending balance	$	2,822			$	2,795
	The reconciliation of income taxes computed using the statutory United States income tax rate and the provision (benefit) for income taxes for continuing operations for the years ended December 31, 2014, 2013, and 2012, are as follows:
		Year Ended December 31,
		2014			2013			2012
	Federal statutory tax rate	(34	)%		(34	)%		(34	)%
	State taxes, net of federal benefit	(1	)%		(1	)%		(3	)%
	Valuation allowance	22	%		37	%		20	%
	Prior year true-ups	17	%		1	%		6	%
	Foreign rate difference	—	%		—	%		2	%
	Permanent differences	(3	)%		(1	)%		11	%
	Tax credits	(1	)%		(2	)%		—	%
	Income tax expense	—	%		—	%		2	%
	For the years ended December 31, 2014, 2013, and 2012, the Company’s effective tax rate differs from the federal statutory rate principally due to net operating losses and other temporary differences for which no benefit was recorded.

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies	COMMITMENTS AND CONTINGENCIES
	Operating Leases
	In December 2011, the Company entered into a five year lease agreement for its headquarters location in San Diego, California expiring December 31, 2016. The Company has an option to extend the lease an additional five years. The lease term contains a base rent of approximately $24,000 per month with 3% annual escalations, plus a supplemental real estate tax and operating expense charge to be determined annually. The Company received a five month base rent abatement with the lease agreement. This abatement is recoverable by the landlord on a straight line amortized basis over 60 months should the Company terminate the lease early for any reason.
	In June 2014, the Company entered into a two and one-half year sublease agreement for additional office space within the same building as its headquarters location in San Diego, California expiring December 31, 2016.
	For the years ended December 31, 2014, 2013, and 2012, rent expense for continuing operations totaled $0.4 million for each year.
	Future minimum rental payments under operating leases as of December 31, 2014 are as follows (in thousands):
	2015	$	515
	2016	416
	Total	$	931
	The Company has significant contractual obligations related to its clinical trial expenditures with clinical research organizations (“CROs”). As of December 31, 2014, net open purchase orders which include obligations to our CROs, less any accruals or invoices charged or amounts paid, totaled approximately $5.3 million. These payments are generally cancellable upon notice and do not have any penalties upon cancellation and therefore these obligations are not included in the table above.
	Additionally, certain employees have agreements that provide for severance compensation in the event of termination or a change in control. These agreements can provide for a severance payment of up to 12 months of base salary and bonus in effect at the time of termination and continued health benefits at the Company’s cost for up to 12 months.
	Legal Matters
	The Company is a party to certain litigation that is either judged to be not material or that arises in the ordinary course of business from time to time. The Company intends to vigorously defend its interests in these matters. The Company expects that the resolution of these matters will not have a material adverse effect on its business, financial condition or results of operations. However, due to the uncertainties inherent in litigation, no assurance can be given as to the outcome of these proceedings.

Selected_Quarterly_Financial_I

Selected Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Information (Unaudited)	SELECTED QUARTERLY FINANCIAL INFORMATION (Unaudited)
	The following table presents the Company’s unaudited quarterly results of operations for the years ended December 31, 2014 and 2013 (in thousands, except per share data):
			2014
			1st Quarter			2nd Quarter			3rd Quarter			4th Quarter
	Total revenue		$	—		$	5,454		$	1,898		$	1,907
	Gross profit (loss)		—			5,379			1,413			1,549
	Loss (income) from continuing operations		(3,262		)	1,205			(3,132		)	(17,288		)
	Income (loss) from discontinued operations		—			672			19			—
	Net loss (income)		(3,262		)	1,877			(3,113		)	(17,288		)
	Basic loss (income) per share
	(Loss) income from continuing operations		(0.09		)	0.03			(0.08		)	(0.40		)
	(Loss) income from discontinued operations		—			0.02			—			—
	Net loss		(0.09		)	0.05			(0.08		)	(0.40		)
	Diluted loss (income) per share
	Loss from continuing operations		(0.09		)	0.03			(0.08		)	(0.40		)
	(Loss) income from discontinued operations		—			0.02			—			—
	Net loss		$	(0.09	)	$	0.05		$	(0.08	)	$	(0.40	)
			2013 (1)
			1st Quarter			2nd Quarter			3rd Quarter			4th Quarter
	Total revenue		$	929		$	1,192		$	28		$	362
	Gross profit (loss)		(922		)	490			13			299
	Loss from continuing operations		(6,950		)	(4,086		)	(3,199		)	(1,635		)
	Loss from discontinued operations		(1,723		)	151			214			290
	Net loss		(8,673		)	(3,935		)	(2,985		)	(1,345		)
	Basic and diluted loss per share
	Loss from continuing operations		(0.23		)	(0.12		)	(0.09		)	(0.04		)
	Loss from discontinued operations		(0.06		)	—			0.01			—
	Net loss		$	(0.29	)	$	(0.12	)	$	(0.08	)	$	(0.04	)
	-1	In June 2013, the Company determined that the BQ Kits division would be offered for sale to qualified buyers and in July 2013, it was sold to an unrelated third-party. For all quarters included above, it is presented as discontinued operations.

Organization_and_Summary_of_Si1

Organization and Summary of Signifcant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Presentation and Consolidation	Basis of Presentation and Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. Certain prior year items have been reclassified to conform to the current year presentation.
Use of Estimates	Use of Estimates
	The preparation of these consolidated financial statements in conformity with generally accepted accounting principles (“GAAP”) requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. The Company’s most significant estimates relate to whether revenue recognition criteria have been met, accounting for clinical trials, the valuation of stock based compensation, the impairment of long-lived assets and valuation allowances for the Company’s deferred tax assets. The Company’s actual results may differ from these estimates under different assumptions or conditions.
Liquidity	Liquidity
	The accompanying consolidated financial statements have been prepared on a basis that contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company had an accumulated deficit of approximately $289.9 million as of December 31, 2014, recorded a net loss of approximately $21.8 million for the year ended December 31, 2014 and has principally been financed through the sale of its common stock and other equity securities, debt financing and up-front payments received from commercial partners for the Company’s products under development. Funds raised in recent periods from the sale of common stock include approximately 1) $15.8 million from the Company’s May 2013 follow-on public offering, 2) $3.7 million in net proceeds during 2014 from the sale of common stock from its committed equity financing facility with Aspire Capital Fund, LLC (“Aspire Capital”) (see note 7 for further details) and 3) $2.2 million in net proceeds during 2014 from the sale of common stock via its “at-the-market” (“ATM”) stock selling facility, which was terminated in August 2014. These and other cash-generating activities should not necessarily be considered an indication of the Company’s ability to raise additional funds in the future.
	In February 2015, the Company entered into subscription agreements with certain purchasers pursuant to which it agreed to sell an aggregate of 6,043,955 shares of its common stock and issued warrants to purchase up to an additional 3,021,977 shares of its common stock.  Each share of common stock was priced at $1.82 and included one half of a warrant to purchase a share of common stock. The warrants have an exercise price of $1.82 per share, are exercisable beginning six months and one day after the date of issuance and expire on the seventh anniversary of the date of issuance. The total net proceeds from the offering were $10.8 million after deducting expenses of approximately $0.2 million. The subscription agreements require that the Company obtain permission from certain of the purchasers prior to selling shares under its committed equity financing facility.
	Based upon its current operating plan, the access to additional capital under its committed equity financing facility, potential to borrow an additional amount of up to $5.0 million under our credit facility, and the $10.8 million received from the Company’s February 2015 financing, the Company believes it has sufficient cash to fund its on-going operations through the first quarter of 2016.
	Based on its recurring losses, negative cash flows from operations and working capital levels, the Company will need to raise substantial additional funds to finance its operations. If the Company is unable to maintain sufficient financial resources, including by raising additional funds when needed, its business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that the Company will be able to obtain the needed financing on reasonable terms or at all. Additionally, equity or debt financings may have a dilutive effect on the holdings of the Company’s existing stockholders.
Cash and Cash Equivalents	Cash and Cash Equivalents
	Cash equivalents represent all highly liquid investments with an original maturity date of three months or less and were not significant as of December 31, 2014 and 2013.
Restricted Cash	Restricted Cash
	Short term restricted cash of $0.3 million is primarily restricted cash held in escrow for environmental remediation services to be performed and for taxes in connection with the sale of our New Jersey facility, both of which are the obligation of the Company. The Company has recorded a liability for the environmental remediation as well as tax liabilities, both of which are included in accrued liabilities. These liabilities represent the best estimate of the fair value of the total obligations and are expected to be satisfied within the current year and are therefore classified as current restricted cash and current liabilities, respectively.
Concentration of Credit Rsk	Concentration of Credit Risk
	From time to time, the Company maintains cash in bank accounts that exceed the FDIC insured limits. The Company has not experienced any losses on its cash accounts. It performs credit evaluations of its customers, but generally does not require collateral to support accounts receivable. Laboratoires Majorelle, Recordati Ireland Ltd., and Hexal AG accounted for approximately 45%, 27%, and 27%, respectively, of total revenues during the year ended December 31, 2014. In addition, one of these companies comprised 75% of the Company’s accounts receivable as of December 31, 2014.
Inventories	Inventory Valuation
	Inventories are stated at the lower of cost or estimated realizable value. The Company capitalizes inventory costs associated with its products after regulatory approval when, based on management's judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes-down such inventories as appropriate. In addition, the Company’s products are subject to strict quality control and monitoring which is performed throughout the manufacturing process, which takes place at its contract manufacturer. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to cost of sales to write down such inventory to its estimated realizable value.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets. The Company estimates useful lives as follows:
	•	Machinery and equipment: three to five years
	•	Furniture and fixtures: ten years
	•	Computer software: five years
	Amortization of leasehold improvements and capital lease equipment is provided on a straight-line basis over the shorter of their estimated useful lives or the lease term. The costs of additions and betterments are capitalized, and repairs and maintenance costs are charged to operations in the periods incurred (see note 5 for further details).
Leases	Leases
	Leases are reviewed and classified as capital or operating at their inception. The Company records rent expense associated with operating leases on a straight-line basis over the term of the lease. The difference between rent payments and straight-line rent expense is recorded as deferred rent in accrued liabilities.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	The Company reviews for impairment of long-lived assets whenever events or circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. If such assets are considered impaired, the amount of the impairment loss recognized is measured as the amount by which the carrying value of the asset exceeds the fair value of the asset, fair value being determined based upon future cash flows or appraised values, depending on the nature of the asset.
Debt Issuance Costs	Debt Issuance Costs
	Amounts paid related to debt financing activities are capitalized and amortized over the term of the loan.
Revenue Recognition	Revenue Recognition
	The Company generates revenues from the licensing of technology rights and the sale of products, and historically, from the performance of pre-clinical testing services and contract sales services. Payments received under commercial arrangements, such as the licensing of technology rights, may include non-refundable fees at the inception of the arrangements, milestone payments for specific achievements designated in the agreements, and royalties on the sale of products.
	The Company recognizes revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the Company’s price to the buyer is fixed or determinable; and (4) collectability is reasonably assured.
	License Fee Revenue
	Consideration received for the Company’s license arrangements may consist of non-refundable upfront license fees, various performance or sales milestones, royalties upon sales of product, and the delivery of product and/or research services to the licensor. The Company considers a variety of factors in determining the appropriate method of accounting under its license agreements, including whether the various elements can be separated and accounted for individually as separate units of accounting. Deliverables under the arrangement will be separate units of accounting, provided (i) a delivered item has value to the customer on a standalone basis; and (ii) if the arrangement includes a general right of return relative to the delivered item and delivery or performance of the undelivered item is considered probable and substantially in the Company’s control.
	The Company accounts for revenue arrangements with multiple elements by separating and allocating consideration in a multiple-element arrangement according to the relative selling price of each deliverable. If an element can be separated, an amount is allocated based upon the relative selling price of each element. The Company determines the relative selling price of a separate deliverable using the price it charges other customers when it sells that product or service separately; however, if the product or service is not sold separately and third party pricing evidence is not available, the Company will use its best estimate of selling price.
	The Company defers recognition of non-refundable upfront fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable fee has no utility to the licensee that is separate and independent of its performance under the other elements of the arrangement. Non-refundable, up-front fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on its part are recognized as revenue when the license term commences and the licensed data, technology and/or compound is delivered. The specific methodology for the recognition of the revenue is determined on a case-by-case basis according to the facts and circumstances of the applicable agreement.
	Product Sales Revenue
	The Company has supply and manufacturing agreements with certain of its licensee partners for the manufacture and delivery of Vitaros® product. These agreements do not permit the Company’s licensee partners to return product, unless the product sold to the licensee partner is short-dated as defined in each respective license agreement. In those cases, the Company defers revenue recognition on these shipments until the right of return no longer exists, which is the earlier of: (i) evidence that the product has been sold through to the end customer or (ii) the right of return expires. As such, the Company does not have a sales and returns allowance recorded as of December 31, 2014.
	In 2014, the Company commenced shipping of its Vitaros® product to its licensee partners and recognized product sales revenue on certain of these shipments since the criteria for revenue recognition was met.
	Royalty Revenue
	The Company relies on its commercial partners to sell its product, Vitaros®, in approved markets. The Company receives royalties from licensee partners based upon the amount of sales of licensed Vitaros® product consummated by its commercial partners. Royalty revenues are computed based on sales reported to the Company by its licensee partners on a quarterly basis and agreed upon royalty rates for the respective license agreement.
	Contract Service Revenue
	Revenue from contract sales services resulted primarily from the Company’s former subsidiaries, Scomedica SAS, NexMed Europe SAS and NexMed Pharma SAS (the “French Subsidiaries”). The revenue was based on the number of medical visits plus an incentive based on the sales growth of the targeted pharmaceutical products. Revenue associated with medical visits was recognized in the accounting period in which services were rendered. For research services, the Company determined the period in which the performance obligation occurred and recognized revenue using the proportional performance method when the level of effort to complete its performance obligations under an arrangement was able to be reasonably estimated. The Company does not anticipate future revenues from contract services.
Cost of Product Sales and Deferred Cost of Product Sales	Cost of Product Sales
	The Company’s cost of product sales includes direct material and manufacturing overhead associated with the production of inventories. Cost of product sales is also affected by manufacturing efficiencies, allowances for scrap or expired material and additional costs related to initial production quantities of new products.
	Deferred Cost of Product Sales
	Deferred cost of product sales is stated at the lower of cost or net realizable value and includes product sold where title has transferred, but the criteria for revenue recognition have not been met. The Company’s deferred cost of product sales is included in prepaid expenses and other current assets in the consolidated balance sheets.
Research and Development	Research and Development
	Research and development costs are expensed as incurred and include the cost of compensation and related expenses, as well as expenses for third parties who conduct research and development on the Company’s behalf, pursuant to development and consulting agreements in place.
Income Taxes	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax assets will not be realized.
	The Company also follows the provisions of accounting for uncertainty in income taxes which prescribes a model for the recognition and measurement of a tax position taken or expected to be taken in a tax return, and provides guidance on derecognition, classification, interest and penalties, disclosure and transition.
Loss Per Common Share	Loss per Common Share
	Basic and diluted net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding for the respective period, without consideration of common stock equivalents as they would have an anti-dilutive effect on per share amounts.
Stock-Based Compensation	Stock-Based Compensation
	The estimated grant date fair value of stock options granted to employees and directors is calculated based upon the closing stock price of the Company’s common stock on the date of the grant and recognized as stock-based compensation expense over the expected service period. The Company estimates the fair value of each option award on the date of grant using the Black-Scholes option pricing model.
Segment Information	Segment Information
	The Company operates under one segment which develops pharmaceutical products.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In November 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share is More Akin to Debt or to Equity. This update clarifies how current guidance should be interpreted in evaluating the economic characteristics and risks of a host contract in a hybrid financial instrument that is issued in the form of a share. In addition, it clarifies that in evaluating the nature of a host contract, an entity should assess the substance of the relevant terms and features (that is, the relative strength of the debt-like or equity-like terms and features given the facts and circumstances) when considering how to weight those terms and features. The effects of initially adopting the new standard should be applied on a modified retrospective basis to existing hybrid financial instruments issued in a form of a share as of the beginning of the fiscal year for which the amendments are effective. Retrospective application is permitted to all relevant prior periods. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company is currently in the process of evaluating whether the adoption of this update will have a material effect on its consolidated financial statements and related disclosures.
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements -Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this update will require management to assess, at each annual and interim reporting period, the entity’s ability to continue as a going concern and, if management identifies conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued, to disclose in the notes to the entity’s financial statements the principal conditions or events that raised substantial doubt about the entity’s ability to continue as a going concern, management’s evaluation of their significance, and management’s plans that alleviated or are intended to alleviate substantial doubt about the entity’s ability to continue as a going concern. This new standard is effective for annual periods ending after December 15, 2016 and early application is permitted. The Company is currently in the process of evaluating whether the adoption of this update will have a material effect on its consolidated financial statements and related disclosures.
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires entities to recognize revenue in the way it expects to be entitled for the transfer of promised goods or services to customers. This pronouncement is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the effect that this pronouncement will have on its financial statements and related disclosures.
	In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. This ASU raises the threshold for a disposal to qualify as discontinued operations and requires new disclosures for individually material disposal transactions that do not meet the definition of a discontinued operation. Under the new standard, companies report discontinued operations when they have a disposal that represents a strategic shift that has or will have a major impact on operations or financial results. This update will be applied prospectively and is effective for annual periods, and interim periods within those years, beginning after December 15, 2014. Early adoption is permitted provided the disposal was not previously disclosed. This update will not have a material impact on the Company's reported results of operations and financial position.

Organization_and_Summary_of_Si2

Organization and Summary of Signifcant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Securities That Could Potentially Decrease Net Loss Per Share	The following securities that could potentially decrease net loss per share in the future are not included in the determination of diluted loss per share as they are anti-dilutive and are as follows:
			Year Ended December 31,
			2014		2013			2012
	Outstanding stock options		3,955,548		2,351,237			2,213,916
	Outstanding warrants		6,859,682		6,185,492			3,205,492
	Unvested restricted stock		—		26,728			112,705
	Convertible notes payable		—		1,065,891			1,544,402
			10,815,230		9,629,348			7,076,515
Schedule of Revenues and Net Long-Lived Assets by Geographic Area	Revenues by geographic area for the Company’s continuing operations are as follows (in thousands):
			Year Ended December 31,
			2014			2013			2012
	France		$	4,150		$	921		$	2,970
	Europe- Other		5,109			1,590			2,475
	North America		—			—			2,500
			$	9,259		$	2,511		$	7,945
	-1	Amounts included in Europe-other have not been broken out by country as it is impractical to do so given the nature and structure of the license agreements which cover multiple territories. See note 2 for further details related to these agreements.

Ceased_and_Discontinued_Operat1

Ceased and Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Schedule of Gain on Deconsolidation of Former French Subsidiaries	As a result, during the second quarter of 2014, the Company released the approximate $2.8 million liability previously recorded in connection with the deconsolidation of the former French Subsidiaries and recognized approximately $0.8 million as a gain on deconsolidation as follows:
	Release of deconsolidation liability	$	2.8
	Less: Payments made by Majorelle on the Company’s behalf	(2.0		)
	Gain on deconsolidation of former French Subsidiaries	$	0.8

Other_Financial_Information_Ta

Other Financial Information (Tables)	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Inventory	Inventory is comprised of the following (in thousands):
		December 31,
		2014			2013
	Raw materials	$	106		$	209
	Work in process	169			127
	Inventory	$	275		$	336
Property and Equipment	Property and equipment are comprised of the following (in thousands):
		December 31,
		2014			2013
	Leasehold improvements	$	43		$	20
	Machinery and equipment	1,385			847
	Capital lease equipment	76			76
	Computer software	142			134
	Furniture and fixtures	37			34
	Total property and equipment	1,683			1,111
	Less: accumulated depreciation and amortization	(325		)	(156		)
	Property and equipment, net	$	1,358		$	955
Accrued Expenses	Accrued expenses are comprised of the following (in thousands):
		December 31,
		2014			2013
	Deferred consideration to Forendo (Note 3)	$	2,500		$	—
	Outside research and development services	838			298
	Professional fees	625			997
	Deferred compensation	176			184
	Environmental remediation	126			168
	Other	290			472
		$	4,555		$	2,119
Other Long Term Liabilities	Other long term liabilities are comprised of the following (in thousands):
		December 31,
		2014			2013
	Deferred compensation	$	312		$	487
	Deferred rent	41			80
	Capital lease payable	5			11
		$	358		$	578

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Summary of Debt	The Company’s notes payable balance as of December 31, 2014 consisted of the following (in thousands):
	Notes payable	$	5,000
	Add: accretion of final payment fee	16
	Less: unamortized debt discount	(237		)
		4,779
	Less: current portion of notes payable, net	(153		)
		$	4,626
	The Company’s convertible notes payable balance as of December 31, 2013 consisted of the following (in thousands):
	Convertible notes payable	$	4,000
	Less: conversions to common stock	(1,250		)
		2,750
	Less: unamortized debt discount	(150		)
		$	2,600

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Summary of Warrant Activity	A summary of warrant activity during the year ended December 31, 2014 is as follows:
		Common Shares		Weighted			Weighted
		Issuable upon		Average			Average
		Exercise		Exercise			Remaining
				Price			Contractual
							Life (in years)
	Outstanding at December 31, 2013	6,185,492		$	4.01		3.6
	Issued	674,190		2.19
	Exercised	—		—
	Cancelled	—		—
	Outstanding at December 31, 2014	6,859,682		3.83			2.7
	Exercisable at December 31, 2014	6,859,682		$	3.83		2.7
	The following table shows the number of outstanding warrants by exercise price and date of expiration as of December 31, 2014:
	Shares Issuable Upon Exercise		Exercise Price			Expiration Date
	716,356		$	2.27		Oct-15
	480,392		$	2.55		Dec-15
	2,469,136		$	5.25		Feb-17
	3,000,000		$	3.4		May-18
	193,798		$	1.29		Jan-24
	6,859,682

Equity_Compensation_Plans_Tabl

Equity Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Activity	A summary of stock option activity during the year ended December 31, 2014 is as follows:
		Number of			Weighted				Weighted		Total
		Shares			Average				Average Remaining		Aggregate
					Exercise				Contractual		Intrinsic
					Price				Life (in years)		Value
	Outstanding as of December 31, 2013	2,351,237			$	3.1			8.6		$	444,012
	Granted	2,173,506			1.96
	Exercised	—			—
	Cancelled	(569,195	)		2.37
	Outstanding as of December 31, 2014	3,955,548			$	2.58			7.5		$	—
	Vested or expected to vest as of December 31, 2014	3,837,625			$	2.61			7.4		$	—
	Exercisable as of December 31, 2014	1,613,222			$	3.42			5.1		$	—
Schedule of Nonvested Restricted Stock Units Activity	A summary of stock award activity during the year ended December 31, 2014 is as follows:
		Number of			Weighted Average
		Shares			Grant Date Fair Value Per Share
	Nonvested as of December 31, 2013	26,728			$	4.58
	Granted	—			—
	Vested	(26,728	)		4.58
	Forfeited	—			—
	Nonvested as of December 31, 2014	—			$	—
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The following table presents the weighted average assumptions used by the Company to estimate the fair value of stock option grants using the Black-Scholes option-pricing model, as well as the resulting weighted average fair values:
		Year Ended December 31,
		2014				2013				2012
	Risk-free interest rate	1.58% - 1.96%				1.08% - 1.85%				0.6% - 1.1%
	Volatility	80.75		%		70		%		70		%
	Dividend yield	0		%		0		%		0		%
	Expected term	5.25- 6.08 years				5.25-6.25 years				5.25-6.0 years
	Forfeiture rate	3.6		%		2.66		%		2.66		%
	Weighted average fair value	$	1.25			$	1.52			$	1.95
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan	The following table summarizes the total stock-based compensation expense resulting from share-based awards recorded in the Company’s consolidated statements of operations (in thousands):
			Year Ended December 31,
			2014				2013				2012
	Research and development		$	267			$	225			$	299
	General and administrative		1,464				1,767				2,618
			$	1,731			$	1,992			$	2,917

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Expense or Benefit	Details of income tax expense are as follows (in thousands):
		December 31,
		2014				2013				2012
	Current
	Federal	$	—			$	—			$	—
	State	—				—				—
	Foreign	—				—				—
	Total current	—				—				—
	Deferred
	Federal	—				—				—
	State	—				—				—
	Foreign	—				—				516
	Total deferred	—				—				516
	Total income tax expense	$	—			$	—			$	516
Deferred Tax Assets	Deferred tax assets consist of the following:
		December 31,
		2014				2013
	Net operating tax loss carryforwards	$	60,380			$	59,927
	Research and development tax credits	534				404
	Deferred compensation	168				269
	Other accruals and reserves	670				504
	Basis of intangible assets	4,610				(45		)
	Total deferred tax asset	66,362				61,059
	Less valuation allowance	(66,362		)		(61,059		)
	Net deferred tax asset	$	—			$	—
Reconciliation of Unrecognized Tax Benefits	A reconciliation of the Company’s unrecognized tax benefits from January 1, 2014 through December 31, 2014 is provided in the following table (in thousands):
		Year Ended December 31,
		2014				2013
	Beginning balance	$	2,795			$	2,879
	Increase in current period positions	34				41
	Decrease in prior period positions	(7		)		(125		)
	Ending balance	$	2,822			$	2,795
Reconciliation of Income Taxes	The reconciliation of income taxes computed using the statutory United States income tax rate and the provision (benefit) for income taxes for continuing operations for the years ended December 31, 2014, 2013, and 2012, are as follows:
		Year Ended December 31,
		2014			2013			2012
	Federal statutory tax rate	(34	)%		(34	)%		(34	)%
	State taxes, net of federal benefit	(1	)%		(1	)%		(3	)%
	Valuation allowance	22	%		37	%		20	%
	Prior year true-ups	17	%		1	%		6	%
	Foreign rate difference	—	%		—	%		2	%
	Permanent differences	(3	)%		(1	)%		11	%
	Tax credits	(1	)%		(2	)%		—	%
	Income tax expense	—	%		—	%		2	%

Commitments_And_Contingencies_

Commitments And Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Rental Payments under Operating Leases	Future minimum rental payments under operating leases as of December 31, 2014 are as follows (in thousands):
	2015	$	515
	2016	416
	Total	$	931

Selected_Quarterly_Financial_I1

Selected Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following table presents the Company’s unaudited quarterly results of operations for the years ended December 31, 2014 and 2013 (in thousands, except per share data):
			2014
			1st Quarter			2nd Quarter			3rd Quarter			4th Quarter
	Total revenue		$	—		$	5,454		$	1,898		$	1,907
	Gross profit (loss)		—			5,379			1,413			1,549
	Loss (income) from continuing operations		(3,262		)	1,205			(3,132		)	(17,288		)
	Income (loss) from discontinued operations		—			672			19			—
	Net loss (income)		(3,262		)	1,877			(3,113		)	(17,288		)
	Basic loss (income) per share
	(Loss) income from continuing operations		(0.09		)	0.03			(0.08		)	(0.40		)
	(Loss) income from discontinued operations		—			0.02			—			—
	Net loss		(0.09		)	0.05			(0.08		)	(0.40		)
	Diluted loss (income) per share
	Loss from continuing operations		(0.09		)	0.03			(0.08		)	(0.40		)
	(Loss) income from discontinued operations		—			0.02			—			—
	Net loss		$	(0.09	)	$	0.05		$	(0.08	)	$	(0.40	)
			2013 (1)
			1st Quarter			2nd Quarter			3rd Quarter			4th Quarter
	Total revenue		$	929		$	1,192		$	28		$	362
	Gross profit (loss)		(922		)	490			13			299
	Loss from continuing operations		(6,950		)	(4,086		)	(3,199		)	(1,635		)
	Loss from discontinued operations		(1,723		)	151			214			290
	Net loss		(8,673		)	(3,935		)	(2,985		)	(1,345		)
	Basic and diluted loss per share
	Loss from continuing operations		(0.23		)	(0.12		)	(0.09		)	(0.04		)
	Loss from discontinued operations		(0.06		)	—			0.01			—
	Net loss		$	(0.29	)	$	(0.12	)	$	(0.08	)	$	(0.04	)
	-1	In June 2013, the Company determined that the BQ Kits division would be offered for sale to qualified buyers and in July 2013, it was sold to an unrelated third-party. For all quarters included above, it is presented as discontinued operations.

Organization_and_Summary_of_Si3

Organization and Summary of Signifcant Accounting Policies - Additional Information (Detail) (USD $)

3 Months Ended

12 Months Ended

1 Months Ended

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

31-May-13

Feb. 28, 2015

Aug. 31, 2014

Oct. 17, 2014

Segment

Basis of Presentation

Retained earnings (accumulated deficit)

$289,852,000

$268,066,000

$289,852,000

$268,066,000

Net income (loss)

17,288,000

3,113,000

-1,877,000

3,262,000

1,345,000

2,985,000

3,935,000

8,673,000

21,786,000

16,938,000

31,771,000

Proceeds from issuance of common stock

5,913,000

16,612,000

20,410,000

Warrants issued (in shares)

193,798

Exercise Price

$2.55

Cash and cash equivalent, maturity period

3 months

Restricted cash held in escrow

300,000

300,000

Number of operating segments

1

Open purchase orders, net

5,300,000

5,300,000

Follow-on public offering

Basis of Presentation

Proceeds from issuance of common stock

15,800,000

Aspire Capital Common Stock Purchase Agreement

Basis of Presentation

Proceeds from issuance of common stock

3,700,000

At-the-market stock sales

Basis of Presentation

Proceeds from issuance of common stock

2,200,000

Machinery and Equipment | Minimum

Basis of Presentation

Useful lives of property and equipment

3 years

Machinery and Equipment | Maximum

Basis of Presentation

Useful lives of property and equipment

5 years

Furniture and Fixtures

Basis of Presentation

Useful lives of property and equipment

10 years

Computer Software

Basis of Presentation

Useful lives of property and equipment

5 years

Subsequent Event

Basis of Presentation

Proceeds from issuance of common stock and warrants, net of issuance cost

10,800,000

Stock and warrant issuance costs

200,000

Common Stock | Subsequent Event

Basis of Presentation

Warrants issued (in shares)

3,021,977

Exercise Price

$1.82

Common Stock

Basis of Presentation

Issuance of common stock, net of offering costs (shares)

2,400,000

255,161

Common Stock | Subsequent Event

Basis of Presentation

Issuance of common stock, net of offering costs (shares)

6,043,955

Loan And Security Agreement

Basis of Presentation

Line of credit facility, maximum borrowing capacity

10,000,000

Loan And Security Agreement | Common Stock

Basis of Presentation

Exercise Price

$1.29

Loan And Security Agreement | Term Loan 2

Basis of Presentation

Line of credit facility, maximum borrowing capacity

$5,000,000

Accounts Receivable

Basis of Presentation

Number of companies

1

1

Concentration risk, percentage

75.00%

Accounts Receivable | Customer One

Basis of Presentation

Concentration risk, percentage

45.00%

Accounts Receivable | Customer Two

Basis of Presentation

Concentration risk, percentage

27.00%

Accounts Receivable | Customer Three

Basis of Presentation

Concentration risk, percentage

27.00%

Organization_and_Summary_of_Si4

Organization and Summary of Signifcant Accounting Policies - Weighted Average Common Stock Equivalents Outstanding During The Respective Periods (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of securities that are antidilutive	10,815,230	9,629,348	7,076,515
Outstanding stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of securities that are antidilutive	3,955,548	2,351,237	2,213,916
Outstanding warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of securities that are antidilutive	6,859,682	6,185,492	3,205,492
Unvested restricted stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of securities that are antidilutive	0	26,728	112,705
Convertible notes payable
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of securities that are antidilutive	0	1,065,891	1,544,402

Organization_and_Summary_of_Si5

Organization and Summary of Signifcant Accounting Policies - Geographic Information (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Revenue	$1,907	$1,898	$5,454	$0	$362	$28	$1,192	$929	$9,259	$2,511	$7,945
France
Segment Reporting Information [Line Items]
Revenue									4,150	921	2,970
Europe- Other
Segment Reporting Information [Line Items]
Revenue									5,109	1,590	2,475
North America
Segment Reporting Information [Line Items]
Revenue									$0	$0	$2,500

Vitaros_Licensing_Agreements_A

Vitaros Licensing Agreements - Additional Information (Detail)

12 Months Ended

36 Months Ended

49 Months Ended

36 Months Ended

12 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

12 Months Ended

14 Months Ended

1 Months Ended

11 Months Ended

28 Months Ended

72 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Feb. 28, 2015

Jan. 31, 2014

Dec. 31, 2013

Sep. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Feb. 28, 2014

Dec. 31, 2014

Dec. 31, 2014

Jun. 30, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

USD ($)

USD ($)

USD ($)

Abbott License Agreement

Bracco License Agreement

Bracco License Agreement

Sandoz License Agreement

Sandoz License Agreement

Sandoz License Agreement

Sandoz License Agreement

Sandoz License Amendment Agreement

Sandoz License Amendment Agreement

Sandoz License Amendment Agreement

Sandoz License Amendment Agreement

Sandoz License Amendment Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Majorelle License Agreement

Recordati License Agreement

Recordati License Agreement

Recordati License Agreement

Recordati License Agreement

Recordati License Agreement

Recordati License Agreement

Takeda Agreement

Takeda Agreement

Actavis plc

USD ($)

USD ($)

EUR (€)

USD ($)

Maximum

Maximum

Vitaros

USD ($)

USD ($)

Maximum

Maximum

Vitaros

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Maximum

Maximum

USD ($)

USD ($)

EUR (€)

USD ($)

Maximum

Maximum

Maximum

Maximum

USD ($)

USD ($)

EUR (€)

USD ($)

USD ($)

EUR (€)

Subsequent Event

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

EUR (€)

USD ($)

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Proceeds from licensing agreement

$2,500,000

$1,300,000

$400,000

$200,000

$1,800,000

$2,000,000

$2,500,000

$2,500,000

$1,000,000

$2,500,000

Expected upfront license fees and milestone payments

13,200,000

5,500,000

4,500,000

200,000

200,000

100,000

42,100,000

34,650,000

2,500,000

Deferred revenue

2,000,000

2,500,000

License revenue

8,454,000

941,000

4,276,000

4,000,000

1,000,000

1,000,000

1,000,000

3,000,000

4,000,000

Future expected proceeds from marketing launch milestones

1,500,000

Future expected proceeds from sales milestones

50,700,000

41,750,000

18,800,000

15,500,000

41,900,000

34,500,000

Payments made by Majorelle on behalf of the Company

2,000,000

2,000,000

Future expected proceeds from regulatory milestones

2,000,000

Future expected proceeds from commercial launch payments

1,200,000

1,000,000

Accrued license fees

$2,500,000

$0

$2,000,000

InLicensing_Agreement_Details

In-Licensing Agreement (Details) (USD $)	12 Months Ended			0 Months Ended	1 Months Ended	3 Months Ended	1 Months Ended	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 17, 2014	Oct. 31, 2014	Dec. 31, 2014	Aug. 31, 2014	Sep. 30, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Accrued license fees	$2,500,000	$0				$2,500,000
Research and development	21,288,000	5,123,000	5,375,000
Issuance of common stock, value		792,000
Forendo License Agreement | Option To Purchase A Drug Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payment of license fees					5,000,000
Maximum product license agreement, regulatory milestone payment				45,000,000
Accrued license fees	2,500,000					2,500,000
Maximum product license agreement, commercial milestone payment				260,000,000
Research and development						13,600,000
Transaction costs						200,000
Common Stock
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Issuance of common stock (shares)							255,161	2,400,000
Common Stock | Forendo License Agreement | Option To Purchase A Drug Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Issuance of common stock (shares)				3,600,000
Issuance of common stock, value				$5,900,000

Ceased_and_Discontinued_Operat2

Ceased and Discontinued Operations - Additional Information (Detail)	12 Months Ended			1 Months Ended	3 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014
	USD ($)	USD ($)	USD ($)	Majorelle License Agreement	Majorelle License Agreement	Scomedica
				USD ($)	USD ($)	EUR (€)
Business Acquisition [Line Items]
Loss contingency, damages sought						€ 4,100,000
Payments made by Majorelle on behalf of the Company				2,000,000	2,000,000
Release of deconsolidation liability	2,000,000	0	0		2,800,000
Deconsolidation of former French Subsidiaries	$846,000	$641,000	$0		$800,000

Gain_on_Deconsolidation_Detail

- Gain on Deconsolidation (Details) (USD $)	12 Months Ended			1 Months Ended	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jun. 30, 2014
Business Acquisition [Line Items]
Release of deconsolidation liability	$2,000,000	$0	$0
Gain on deconsolidation of former French Subsidiaries	846,000	641,000	0
Majorelle License Agreement
Business Acquisition [Line Items]
Release of deconsolidation liability					2,800,000
Less: Payments made by Majorelle on the Company’s behalf				-2,000,000	-2,000,000
Gain on deconsolidation of former French Subsidiaries					$800,000

Ceased_and_Discontinued_Operat3

Ceased and Discontinued Operations - Sale of Bio-Quant (Details) (USD $)	12 Months Ended			1 Months Ended	5 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 30, 2014	31-May-14
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of subsidiary	$50,000	$255,000	$250,000
Sale Of Bio Quant Incorporated
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of subsidiary	700,000			600,000	100,000
Gain on disposal of discontinued operations	$700,000

Other_Financial_Information_In

Other Financial Information - Inventory (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$106	$209
Work in process	169	127
Inventory	$275	$336

Other_Financial_Information_Pr

Other Financial Information - Property and Equipment (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Leasehold improvements	$43	$20
Machinery and equipment	1,385	847
Capital lease equipment	76	76
Computer software	142	134
Furniture and fixtures	37	34
Total property and equipment	1,683	1,111
Less: accumulated depreciation and amortization	-325	-156
Property and equipment, net	1,358	955
Depreciation	$200	$100	$200

Other_Financial_Information_Ac

Other Financial Information - Accrued Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Deferred consideration to Forendo	$2,500	$0
Outside research and development services	838	298
Professional fees	625	997
Deferred compensation	176	184
Environmental remediation	126	168
Other	290	472
Accrued expenses	$4,555	$2,119

Other_Financial_Information_Ot

Other Financial Information - Other Long-term Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Deferred compensation	$312	$487
Deferred rent	41	80
Capital lease payable	5	11
Other long term liabilities	$358	$578

Other_Financial_Information_De

Other Financial Information - (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Deferred compensation, current	$176	$184
Chief Executive Officer And President
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Severance payable period	180 months
Deferred compensation, current	$200	$200

Other_Financial_Information_Ga

Other Financial Information - Gain on Contract Settlement (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on contract settlement	$910,000	$534,000	$0
Return of common stock in connection with contract settlement (shares)	388,888
TopoTarget
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Gain on contract settlement		500,000
Business acquisition, value of common stock issued		1,200,000
Contingent consideration, liability		$1,700,000

Debt_Credit_Agreement_Details

Debt - Credit Agreement (Details) (USD $)	0 Months Ended
	Oct. 17, 2014	Dec. 31, 2014
Debt Instrument [Line Items]
Number of securities called by warrants (shares)	480,392	6,859,682
Warrant exercise price (USD per share)	$2.55
Loan And Security Agreement
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$10,000,000
Debt instrument final payment fee, percentage	6.00%
Loan And Security Agreement | Common Stock
Debt Instrument [Line Items]
Number of securities called by warrants (shares)	193,798
Warrant exercise price (USD per share)	$1.29
Loan And Security Agreement | Term Loan 1
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	5,000,000
Interest rate	7.95%
Debt instrument, prepayment fee, percentage	3.00%
Loan And Security Agreement | Term Loan 2
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$5,000,000

Debt_Term_Loans_Details

Debt - Term Loans (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Oct. 17, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Notes payable		$1,225	$2,750
Loan And Security Agreement | Term Loan 1
Debt Instrument [Line Items]
Notes payable	5,000
Add: accretion of final payment fee	16
Less: unamortized debt discount	-237
Long-term Debt	4,779
Less: current portion of notes payable, net	-153
Long-term debt, excluding current maturities	4,626
Interest expense	$100

Debt_2012_Convertible_Notes_De

Debt - 2012 Convertible Notes (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 17, 2014
Debt Instrument [Line Items]
Notes payable			$2,750		$1,225
Shares Issuable Upon Exercise	6,859,682	6,859,682			480,392
Warrant exercise price (USD per share)					$2.55
Loss on extinguishment of debt	$100	($82)	$0	$0
Convertible Note 2012
Debt Instrument [Line Items]
Interest rate					7.00%

Debt_Detail

Debt - (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Oct. 17, 2014
Debt Disclosure [Abstract]
Convertible notes payable	$4,000
Less: conversions to common stock	-1,250
Notes payable	2,750	1,225
Less: unamortized debt discount	-150
Convertible notes payable	$2,600

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt Disclosure [Abstract]
Interest expense	$0.20	$0.50	$0.30

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	12 Months Ended			1 Months Ended		3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 28, 2015	Aug. 31, 2014	Sep. 30, 2014	Oct. 17, 2014
Stockholders Equity Note
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, par value (USD per share)	$0.00	$0.00
Preferred stock shares outstanding (in shares)	0	0
Warrants issued (in shares)	193,798
Proceeds from issuance of common stock	$5,913,000	$16,612,000	$20,410,000
Proceeds from exercise of warrants	0	46,000	40,000
Number of warrants exercised		20,000	17,595
Shares Issuable Upon Exercise	6,859,682						480,392
Warrant exercise price (USD per share)							$2.55
Subsequent Event
Stockholders Equity Note
Proceeds from issuance of common stock and warrants, net of issuance cost				10,800,000
Stock and warrant issuance costs				200,000
Subsequent Event | Common Stock
Stockholders Equity Note
Warrants issued (in shares)				3,021,977
Warrant exercise price (USD per share)				$1.82
At-the-market equity offering
Stockholders Equity Note
Issuance of common stock (shares)	954,922	312,450	515,329
Proceeds from issuance of common stock		800,000	2,000,000
Offerings
Stockholders Equity Note
Proceeds from exercise of warrants		50,000	40,000
Series A Junior Participating Preferred Stock
Stockholders Equity Note
Preferred stock, shares authorized (in shares)	1,000,000
Series B 8% Cumulative Convertible Preferred Stock
Stockholders Equity Note
Preferred stock, shares authorized (in shares)	800
Preferred stock dividend rate	8.00%
Series C 6% Cumulative Convertible Preferred Stock
Stockholders Equity Note
Preferred stock, shares authorized (in shares)	600
Preferred stock dividend rate	6.00%
Series D Junior Participating Cumulative Preferred Stock
Stockholders Equity Note
Preferred stock, shares authorized (in shares)	50,000
Common Stock
Stockholders Equity Note
Issuance of common stock (shares)					255,161	2,400,000
Common share purchase agreement, shares authorized					22,000,000
Common stock purchase agreement, term					24 months
Common stock purchase agreement, commitment fee, amount					400,000
Common stock, shares authorized, remaining amount						$18,200,000
Weighted average sales price per share (USD per share)					$1.62
Common Stock | Subsequent Event
Stockholders Equity Note
Issuance of common stock (shares)				6,043,955
Common Stock | Loan And Security Agreement
Stockholders Equity Note
Shares Issuable Upon Exercise							193,798
Warrant exercise price (USD per share)							$1.29

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Warrant Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2012
Common shares Issuable upon Exercise
Outstanding at December 31, 2013 (in shares)	6,185,492
Issued (in shares)	674,190
Exercised (in shares)	0
Cancelled (in shares)	0
Outstanding as of December 31, 2014 (in shares)	6,859,682
Exercisable at December 31, 2014 (in shares)	6,859,682
Weighted Average Exercise Price
Outstanding at December 31, 2013 (USD per Share)	$4.01
Issued (USD per Share)	$2.19
Exercised (USD per Share)	$0
Cancelled (USD per Share)	$0
Outstanding at December 31, 2014 (USD per Share)	$3.83
Exercisable at December 31, 2014 (USD per Share)	$3.83
Weighted Average Contractual Life
Outstanding at December 31, 2013 (in years)		3 years 7 months 6 days
Outstanding at December 31, 2014 (in years)	2 years 8 months 6 days
Exercisable at December 31, 2014 (in years)	2 years 8 months 6 days

Stockholders_Equity_Warrants_O

Stockholders' Equity - Warrants Outstanding by Expiration Date (Details) (USD $)	Dec. 31, 2014	Oct. 17, 2014
Class of Warrant or Right [Line Items]
Shares Issuable Upon Exercise	6,859,682	480,392
Exercise Price		$2.55
Oct-15
Class of Warrant or Right [Line Items]
Shares Issuable Upon Exercise	716,356
Exercise Price	2.27
Dec-15
Class of Warrant or Right [Line Items]
Shares Issuable Upon Exercise		480,392
Exercise Price		$2.55
Feb-17
Class of Warrant or Right [Line Items]
Shares Issuable Upon Exercise	2,469,136
Exercise Price	5.25
May-18
Class of Warrant or Right [Line Items]
Shares Issuable Upon Exercise	3,000,000
Exercise Price	3.4
Jan-24
Class of Warrant or Right [Line Items]
Shares Issuable Upon Exercise		193,798
Exercise Price		$1.29

Equity_Compensation_Plans_Addi

Equity Compensation Plans - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award
Common shares authorized for issuance	6,800,000
Common shares available for future grants	1,600,000
Stock options exercisable (number of shares)	1,613,222	752,815	856,868
Aggregate intrinsic value of options exercised		$16,000
Dividend yield	0.00%	0.00%	0.00%
Non Vested Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Unrecognized compensation cost related to non-vested stock options	2,700,000
Unrecognized compensation cost related to non-vested stock options, recognition period (in years)	2 years 10 months 8 days
2012 Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award
Options vesting period	1 year
2012 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award
Options vesting period	4 years
Term of options	10 years

Equity_Compensation_Plans_Summ

Equity Compensation Plans - Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Number of shares
Outstanding as of December 31, 2013 (shares)	2,351,237
Granted (shares)	2,173,506
Exercised (shares)	0
Cancelled (shares)	-569,195
Outstanding as of December 31, 2014 (shares)	3,955,548	2,351,237
Stock options vested or expected to vest as of December 31, 2014 (shares)	3,837,625
Stock options exercisable as of December 31, 2014 (number of shares)	1,613,222	752,815	856,868
Weighted-Average Exercise Price
Beginning balance (USD per share)	$3.10
Granted (USD per share)	$1.96
Exercised (USD per share)	$0
Cancelled (USD per share)	$2.37
Ending balance (USD per share)	$2.58	$3.10
Weighted-average exercise price of vested or expected to vest stock options (USD per share)	$2.61
Weighted-average exercise price of exercisable stock options (USD per share)	$3.42
Weighted Average Remaining Contractual Life (in years)
Outstanding (in years)	7 years 6 months 6 days	8 years 7 months 24 days
Weighted Average Remaining Contractual Life (in years) of vested or expected to vest stock options	7 years 5 months 6 days
Weighted Average Remaining Contractual Life (in years) of exercisable stock options	5 years 1 month
Total Aggregate Intrinsic Value
Beginning Balance	$444,012
Ending Balance	0	444,012
Total aggregate intrinsic value of vested or expected to vest stock options	0
Total aggregate intrinsic value of exercisable stock options	$0

Equity_Compensation_Plans_Summ1

Equity Compensation Plans - Summary Of Restricted Stock Award Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Number of Shares
Nonvested as of December 31, 2013	26,728
Shares granted	0
Shares vested and granted	-26,728
Shares forfeited	0
Nonvested as of December 31, 2014	0
Stock Awards
Weighted Average Grant Date Fair Value Per Share
Nonvested Weighted Average Grant Date Fair Value as of December 31, 2013 (USD per share)	4.58
Shares granted (USD per share)	0
Shares vested and issued (USD per share)	4.58
Shares forfeited (USD per share)	0
Date Fair Value as of December 31, 2014 (USD per share)	0

Equity_Compensation_Plans_Assu

Equity Compensation Plans - Assumptions Of Black-Scholes Option Pricing Model Used In Estimating Fair Value Of Stock Option Grant (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Risk-free interest rate, minimum	1.58%	1.08%	0.60%
Risk-free interest rate, maximum	1.96%	1.85%	1.10%
Volatility	80.75%	70.00%	70.00%
Dividend yield	0.00%	0.00%	0.00%
Forfeiture rate	3.60%	2.66%	2.66%
Weighted average fair value	$1.25	$1.52	$1.95
Minimum
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected term (in years)	5 years 3 months	5 years 3 months	5 years 3 months
Maximum
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Expected term (in years)	6 years 0 months 29 days	6 years 3 months	6 years

Equity_Compensation_Plans_Comp

Equity Compensation Plans - Compensation Expense Resulting From Stock Options And Awards (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award
Stock-based compensation expense	$1,731	$1,992	$2,917
Research and development
Share-based Compensation Arrangement by Share-based Payment Award
Stock-based compensation expense	267	225	299
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award
Stock-based compensation expense	$1,464	$1,767	$2,618

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$174.70
Non current deferred tax benefits	$60.90	$60.30

Income_Taxes_Income_Tax_Expens

Income Taxes - Income Tax Expense or Benefit (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current
Federal	$0	$0	$0
State	0	0	0
Foreign	0	0	0
Total current	0	0	0
Deferred
Federal	0	0	0
State	0	0	0
Foreign	0	0	516
Total deferred	0	0	516
Total income tax expense	$0	$0	$516

Income_Taxes_Deferred_Tax_Asse

Income Taxes - Deferred Tax Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Income Tax Disclosure [Abstract]
Net operating tax loss carryforwards	$60,380	$59,927
Research and development tax credits	534	404
Deferred compensation	168	269
Other accruals and reserves	670	504
Basis of intangible assets	4,610	-45
Total deferred tax asset	66,362	61,059
Less valuation allowance	-66,362	-61,059
Net deferred tax asset	$0	$0

Income_Taxes_Recognition_Of_Un

Income Taxes - Recognition Of Unrecognized Tax Benefits (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Beginning balance	$2,795	$2,879
Increase in current period positions	34	41
Decrease in prior period positions	-7	-125
Ending balance	$2,822	$2,795

Income_Taxes_Reconciliation_Of

Income Taxes - Reconciliation Of Income Taxes (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Federal statutory tax rate	-34.00%	-34.00%	-34.00%
State taxes, net of federal benefit	-1.00%	-1.00%	-3.00%
Valuation allowance	22.00%	37.00%	20.00%
Prior year true-ups	17.00%	1.00%	6.00%
Foreign rate difference	0.00%	0.00%	2.00%
Permanent differences	-3.00%	-1.00%	11.00%
Tax credits	-1.00%	-2.00%	0.00%
Income tax expense	0.00%	0.00%	2.00%

Commitments_And_Contingencies_1

Commitments And Contingencies - Additional Information (Details) (USD $)	12 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 31, 2011
Commitments And Contingencies [Line Items]
Operating lease, rent expense	$400,000
Open purchase orders, net	5,300,000
San Diego California
Commitments And Contingencies [Line Items]
Operating lease, agreement period		5 years
Operating lease, renewal option		5 years
Operating lease, monthly rent		$24,000
Operating leases rent expense percentage of annual escalation		3.00%
Operating lease, rent abatement period		5 months

Commitments_And_Contingencies_2

Commitments And Contingencies - Future Minimum Rental Payments Under Operating Leases (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]
2015	$515
2016	416
Total	$931

Selected_Quarterly_Financial_I2

Selected Quarterly Financial Information (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Total revenue	$1,907	$1,898	$5,454	$0	$362	$28	$1,192	$929	$9,259	$2,511	$7,945
Gross profit (loss)	1,549	1,413	5,379	0	299	13	490	-922	8,341	-120	3,705
Loss (income) from continuing operations	-17,288	-3,132	1,205	-3,262	-1,635	-3,199	-4,086	-6,950	-22,477	-15,870	-25,676
Income (loss) from discontinued operations	0	19	672	0	290	214	151	-1,723	691	-1,068	-6,095
Net loss	($17,288)	($3,113)	$1,877	($3,262)	($1,345)	($2,985)	($3,935)	($8,673)	($21,786)	($16,938)	($31,771)
Income (loss) from continuing operations, per basic share	($0.40)	($0.08)	$0.03	($0.09)
Discontinued operation, income (loss) from discontinued operation, net of tax, per basic share	$0	$0	$0.02	$0
Earnings per share, basic	($0.40)	($0.08)	$0.05	($0.09)
Income (loss) from continuing operations, per diluted share	($0.40)	($0.08)	$0.03	($0.09)
Discontinued operation, income (loss) from discontinued operation, net of tax, per diluted share	$0	$0	$0.02	$0
Earnings per share, diluted	($0.40)	($0.08)	$0.05	($0.09)
Basic and diluted loss per share
Loss from continuing operations (USD per share)					($0.04)	($0.09)	($0.12)	($0.23)	($0.57)	($0.46)	($0.94)
Income (loss) from discontinued operations (USD per share)					$0	$0.01	$0	($0.06)	$0.02	($0.03)	($0.22)
Net loss per share (USD per share)					($0.04)	($0.08)	($0.12)	($0.29)	($0.55)	($0.49)	($1.16)